


MOVING FROM COVID-19

MATHEMATICAL MODELS TO VACCINE DESIGN: THEORY, PRACTICE AND EXPERIENCES



Gobierno de Puebla
Hacer historia. Hacer futuro.



**Secretaría
de Educación**

CONCYTEP
Consejo de Ciencia
y Tecnología del Estado
de Puebla

Editor:
Andrés Fraguela-Collar

Bentham Books

Moving from COVID-19
Mathematical Models to Vaccine Design:
Theory, Practice and Experiences

Edited by

Andrés Fraguera-Collar

Professor and Researcher in Applied Mathematics
Faculty of Physics and Mathematics
Autonomous University of Puebla
Puebla, Mexico

**Moving from COVID-19 Mathematical Models to Vaccine Design:
Theory, Practice and Experiences**

Editor: Andrés Fraguera-Collar

ISBN (Online): 978-981-5051-90-2

ISBN (Print): 978-981-5051-91-9

ISBN (Paperback): 978-981-5051-92-6

© 2022, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2022.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



Contents

Foreword I	i
Foreword II	iv
Foreword III	vi
Preface	viii
Dedication	xii
List of Contributors	xiii
1 An Approach to COVID-19: Current Results, Perspectives and its Study with Mathematical and Computational Modeling Tools	1
1 Introduction.....	2
1.1 Importance	2
1.2 The COVID-19 Pandemic as a Complex Phenomenon.....	4
1.3 Mathematical and Computational Modeling in Epidemiology	8
2 Different Perspectives for the Study of the Disease and the COVID-19 Pandemic .	11
2.1 Action of the Virus at Different Scales of Biological Organization.....	12

2.2	Temporal Evolution of COVID-19 Disease at the Individual Level	20
2.3	Temporal Evolution of the COVID-19 Pandemic at the Country Level and at the Global Level; the Role of Human Mobility.....	33
2.4	Collateral Consequences for Human Health, Society and the Economy; Final Comments	37
3	Mathematical and Computational Modeling of COVID-19: Results and Perspectives	41
3.1	Main Characteristics of Forecasting and Compartmental Models and the Basic Assumptions that Support Them	41
3.2	Renewal Equations: Another Scheme for the Construction of Compartmental Models.....	45
3.3	Methodology for the Application of Compartmental Models of the SIR-Type	47
3.4	What Are Compartmental Epidemiological Models Useful for and What Are Their Limitations?.....	49
3.5	How Are the Components of an Epidemiological Compartmental Model Constructed in Correspondence with the Application It Is Intended for?	53
3.6	Some Important Results Obtained on COVID-19 with the Use of Compartmental Mathematical Models.....	61
3.7	Some Pending Issues in the Collection and Analysis of Data and in the Study of the Mathematical Models, Associated with COVID-19.....	77
4	Concluding Remarks.....	82
5	Consent for Publication	84
6	Conflict of Interest	84
7	Acknowledgements.....	84
	References.....	85

2	Epidemiology of COVID-19	109
1	Introduction.....	110
	1.1 Importance	110
	1.2 Preliminaries	110
2	Coronaviruses of Public Health Importance	111
3	The SARS-CoV-2 Virus.....	112
4	Origin and Evolution of the Pandemic.....	113
5	International Health Regulations and Mechanisms for Preparing and Responding to Threats to Public Health	115
6	What Is a Public Health Emergency of International Concern?	117
7	Global Epidemiological Situation and in Mexico of COVID-19	121
8	Transmission Mechanisms and “Reproduction Number” (R_0).....	125
9	Preventive Measures	127
10	Concluding Remarks.....	131
11	Consent for Publication	133
12	Conflict of Interest.....	133
13	Acknowledgements.....	133
	References.....	134
3	COVID-19 Pathophysiology, Clinical Manifestations, and Drug Treatment	145
1	Introduction.....	147
	1.1 Importance	147
	1.2 Preliminaries	147
2	Pathophysiology of the Disease.....	149
	2.1 Virology	149
	2.2 Inflammatory Response	150
	2.3 Thrombotic Phenomena	153
3	Clinical Manifestations of SARS-CoV-2 Infection.....	155

3.1	Asymptomatic Infection.....	155
3.2	Symptomatic Infection.....	155
3.3	Clinical Manifestations	158
4	Drug Treatment.....	166
4.1	Convalescent Patient Plasma	166
4.2	Remdesivir	168
4.3	Baricitinib.....	170
4.4	Anticoagulation and COVID-19	172
4.5	Steroid Use in COVID-19.....	174
4.6	Tocilizumab	177
5	Concluding Remarks.....	177
6	Consent for Publication	179
7	Conflict of Interest	179
8	Acknowledgements.....	179
	References.....	180
4	Modelling Epidemics: a Perspective on Mathematical Models and Their Use	207
1	Introduction.....	208
1.1	Importance	208
1.2	Preliminaries	208
2	Basic Results of the Kermack-McKendrick Model.....	210
3	More General Models	214
4	Modification of the Basic Models	220
5	Epidemic Curves.....	223
6	Epidemic Interactions	225
7	Concluding Remarks.....	228
8	Consent for Publication	230
9	Conflict of Interest.....	230

10	Acknowledgements.....	230
	References.....	231
5	Data Science: A Useful Tool for Understanding SARS-CoV-2 Information Facts	238
1	Introduction.....	239
	1.1 Importance	239
	1.2 Preliminaries	239
2	Artificial Intelligence: the New Boom	244
3	General Framework of Data Science Projects	247
	3.1 The Data Science Workflow	249
	3.2 Exploratory Data Analysis and Preprocessing.....	250
4	Case Study: the Mexican COVID-19 Data.....	253
	4.1 The Database.....	253
	4.2 Bayesian Networks	257
	4.3 Decision Trees.....	264
5	Concluding Remarks.....	269
6	Consent for Publication	270
7	Conflict of Interest.....	270
8	Acknowledgements.....	270
	References.....	271
6	Epidemic Progression in a Heterogeneously Distributed Population	276
1	Introduction.....	277
	1.1 Importance	277
	1.2 Epidemiological Situation.....	277
	1.3 Epidemiological Modelling.....	279
2	Model Problem for a Heterogeneous Population.....	281

2.1	Basic Reproduction Number	281
2.2	Final Size of the Epidemic	282
2.3	Maximum Number of Infected Individuals.....	284
3	Model with Reinfection	287
3.1	Basic Reproduction Number	288
3.2	Existence of Endemic Equilibrium	289
3.3	Final Size of the Epidemic	292
4	Multipatch Model	295
4.1	Two-Group Single-Patch Model	295
4.2	Two-Group n Patch Model	297
5	Epidemic Progression in Some States in India	300
5.1	Epidemic Progression in Maharashtra	302
5.2	Epidemic Progression in the Neighboring States.....	306
6	Concluding Remarks.....	309
7	Consent for Publication	312
8	Conflict of Interest.....	312
9	Acknowledgements.....	312
	References.....	313
7	Social Inequalities in COVID-19	318
1	Introduction.....	319
1.1	Importance	319
1.2	Preamble.....	319
2	Preliminaries	321

2.1	Context and Health in the Life Course.....	321
2.2	The Right to Health.....	324
2.3	Conceptual Bases for Measuring Social Inequalities Related to Health.....	327
2.4	Common Contexts and Applications of Inequality Measurement	331
2.5	Basic Properties and Desirable Attributes for Health Inequality Indices.....	331
2.6	A Basic Taxonomy of Indices to Measure Inequalities [53]	333
3	Indices for Ordered Categories	335
3.1	Indices Based on Pairwise Comparisons.....	335
3.2	Indices Based on the Regression Model	337
3.3	The Concentration Index (<i>CI</i>)	340
4	Indices for Non-Ordered Categories.....	342
4.1	Indices Based on Pairwise Comparisons.....	342
4.2	Dispersion Indices.....	342
4.3	Indices Based on the Comparison of Two Probability Distributions	344
4.4	Options in Measuring Social Inequalities in Relation to Health.....	350
5	COVID-19 and Inequalities. Some Selected Results	355
6	Concluding Remarks.....	370
7	Consent for Publication	370
8	Conflict of Interest.....	370
9	Acknowledgements.....	371
	References.....	373
8	Statistical Approaches to Understand COVID-19 Severity and Fatality	385
1	Introduction.....	386
1.1	Importance	386
1.2	Preliminaries	386
2	Basic Statistics Applied to COVID-19 Severity	387

2.1	Confirmed Cases, Severity, and Recovery or Death	387
2.2	Burden of COVID-19.....	388
2.3	Cluster Analysis for Patient Stratification.....	389
2.4	Prediction Models for Severity and Fatality.....	390
3	Case-Example: Predictors of COVID-19 Fatality in Cuba	399
3.1	Background	399
3.2	Materials and Methods	400
3.3	Results and Discussion.....	404
3.4	Further Applications of Statistical and Epidemiological Techniques	418
4	Concluding Remarks.....	422
5	Consent for Publication	422
6	Conflict of Interest	422
7	Acknowledgements.....	423
	References.....	424

9 Understanding the Impact of Cuban Immunotherapy Protocols During COVID-19

	Disease: Contributions from Mathematical Modeling and Statistical Approaches	435
1	Introduction.....	436
1.1	Importance	436
1.2	Preliminaries	436
2	Mathematical Model Presentation	437
2.1	Model Assumptions	438
2.2	Model Equations	440
2.3	Model Results	445
3	Itolizumab on COVID-19	452
3.1	Preliminary Evidences from the Clinical Practice	452
4	Concluding Remarks.....	459

5	Consent for Publication	461
6	Conflict of Interest	461
7	Acknowledgements.....	461
	References.....	462
10	Vaccines Against SARS-CoV-2. Eradicating COVID-19	468
1	Introduction.....	469
1.1	Importance	469
1.2	Preliminaries	469
2	Vaccine Development Process	470
2.1	Fast-Track Procedures for COVID-19 Vaccine	473
3	Major COVID-19 Vaccine Approaches.....	474
3.1	Original Virus as Vaccine Platform.....	474
3.2	Other Viruses as Vaccine Platform.....	478
3.3	Genetic Material as Vaccine Platform.....	485
3.4	Protein/Peptides Delivered as Subunit Vaccines.....	493
4	Concluding Remarks.....	497
5	Consent for Publication	498
6	Conflict of Interest.....	498
7	Acknowledgements.....	498
	References.....	499
	Appendix: COVID-19 in Charts	519
	SUBJECT INDEX	754

FOREWORD I

Living and coping with COVID 19, the second pandemic of the millennia after the 2009 influenza pandemic, has posed unprecedented challenges. The world has dealt with pandemics before. Human history has been shaped by diseases that present themselves as epidemic, endemic or pandemic diseases. We have registered pandemics since well before the Christian era, and surely, although no registries are available, they have always accompanied humankind. Some remarkable pandemics, that changed the course of history were the Black Plague in the 14th century that killed a great proportion of the European population, and the Spanish Influenza, that occurred little more than a century ago in 1918-19, and killed well over 40 million people, although some scholars say the number of deaths might have reached more the 100 million.

Circumstances have changed and the world is quite different from what it used to be just a few decades ago. Knowledge, technology and communications have developed in an unprecedented speed in human history in the last century and especially in the last four decades. While these are great achievements, they also pose new challenges. Lifestyles have changed and the world faces global threats such as climate change, overpopulation, undernourishment, non-communicable diseases, the emergence of new potentially pandemic infectious diseases such as COVID-19, and many others that have pushed together the global community in efforts to deal with them in a coordinated fashion. Common targets such as the Sustainable Development Goals prove that leaders all over the world are concerned about the future of human kind, although not all to the same extent.

These efforts, however, have been insufficient, and COVID-19 has shown that much more than meetings, nice documents and good intentions are needed to face current challenges. Confronting COVID-19 has risen several questions that need yet to be answered by scientists as well as politicians. For instance, what was the origin of SARS-CoV-2; how can we deal with health inequities such as differential access to vaccines, or why many governments and country leaders disregarded the World Health organization's recommendations.

In this very complicated scenario, any attempt to better understand and cope with COVID-19 are welcome. This book will surely provide vast and comprehensive knowledge about the pandemic and its development, and the best ways to confront it.

Editor and author, Andrés Fraguela Collar, has brought together several contributors, from different Mexican institutions as well as from highly renowned institutions from other countries in a great effort to try to understand COVID-19.

In chapter 1, readers will find a very thorough and challenging description of the mathematical modelling of pandemics in general and of COVID-19, in particular.

Chapter 2 will guide them through key issues about the epidemiology of infectious diseases. They will get a comprehensive view from chapter 3 about what was known at the time the book was written about how SARS-CoV-2 does its damage, how we, human beings, experience the disease and where were the possible treatment options at that moment.

Chapter 4 is devoted to mathematical modelling of epidemics. Chapter 5 will offer readers a very interesting discussion about the importance of data analysis, and the challenges faced when dealing with something new like COVID-19.

Chapter 6 deals with the epidemic progression of the diseases in a non-homogeneous population. Those who love Mathematics will enjoy this chapter.

Chapter 7 leads the reader through the very important subject of social inequities and their role in the propagation of infectious diseases.

Chapter 8 will update the reader on the statistical approach to understand the severity and fatality of COVID-19.

Chapter 9 is devoted to the Cuban experience, on immunotherapy and the role played by mathematical models of disease progression at the individual level.

Chapter 10 and last explains in a very comprehensive manner many aspects of vaccine development and the challenges it poses.

Throughout the book, the reader will find many graphs, tables and formulas, and a very extensive bibliography in each chapter. This book is an example of a multidisciplinary endeavor. It is no easy reading for those who do not have statistical or mathematical background, but anyhow it will be highly enjoyable for any reader and particularly for those familiar with mathematical concepts and methods.

COVID-19 is evolving in many senses, and it is a challenge to health systems, and at the individual level, to both clinicians and researchers. Modelling it has proved to be a very difficult task and as we learn more about it, we discover that there are yet many things to unveil. With this disease, human kind is walking in uncharted territory.

I recommend the reader to follow on new every day developments, to stick to basic publichealth messages which have proven to be the best defense against the disease and to have in mind that this will not be the last pandemic we will face. There is a very high probability of a new pandemic in the future, although we do not know when or how it will occur. As someone said “the clock is ticking, but we do not know what time it shows...”

Enjoy this book, as it contributes to better understand COVID-19.

Pablo Kuri-Morales
Independent Health Consultant

FOREWORD II

Mathematical modeling of infectious diseases has a long history of being used as a tool to study the mechanisms by which a disease can spread within communities, to predict the direction of an outbreak in a population and to evaluate the effectiveness of therapeutic interventions (*e.g.*, vaccination programs) to control an epidemic. These mathematical models derive from basic theories, the collection of statistical data or both, and they help to define parameters for a variety of infectious diseases, and to estimate the effects of the different interventions.

The appearance of a new human viral infection which causes the disease known as COVID-19, constitutes both a challenge and a test to the usefulness and relevance of mathematical modeling. This coronavirus known as SARS-CoV-2 emerged suddenly in South Asia and rapidly disseminated around the globe. It represents a significant concern because, very few times before, the population of the whole world had to face a disease of such pandemic proportions, that has exposed the lack of preparedness of the health care systems to handle thousands of patients and the limited therapeutic interventions to counteract such disease. Fortunately, rapid action in the development of effective vaccines worldwide and the accelerated emergency approval of these therapeutics has let different countries to combat this disease, increasing survival and reducing the death toll.

Current and emerging problems during the pandemic, and the effectiveness of the vaccine platforms developed to cope with it, will define the future of outbreak control. For example, it is unknown whether this novel coronavirus will establish itself in an endemic form or will it eventually die out. Furthermore, the appearance of variants (also known as mutations in the viral genome of SARS-CoV-2) that increase the capacity of the virus to cause disease (*e.g.*, transmissibility), might increase the capacity of the virus to overcome vaccine protection. Therefore, continuous monitoring of the pandemic is required, not only to evaluate vaccine distribution and coverage, but also to follow up individuals who were infected by SARS-CoV-2, since they could be carriers viral variants that might disseminate through the population.

Mathematical modelling can help decide which interventions to avoid and which to test, or can predict epidemic or pandemic patterns, as well as help understanding the impact of vaccination programs. In this book entitled: “Moving from COVID-19 Mathematical Models to Vaccine Design: Theory, Practice and Experiences”, the authors provide a perspective on how to attack a present

problem in public health with mathematical tools, that can guide the decision making related to COVID-19 epidemiology and vaccine production and distribution. But why is this book different from others already published on mathematical modelling? First, the authors of this book are from different countries that are significantly affected by the disease. Second, the book presents a balance set of basic and applied chapters describing topics from disease progression and prevention to those models that could be used in different scenarios. The aim of the book is to present the COVID-19 pandemic as a complex public health problem, that requires the participation of multidisciplinary and interdisciplinary groups of experts to tackle the problems associated with the disease, and demonstrate the role mathematical and computational modeling had during the course and evolution of the pandemic.

The book is divided into 10 chapters. Chapters 1, 4 and 6 introduce mathematical and computational models that can be used to study the COVID-19 pandemic and understand the epidemiology of the disease. Chapters 2 and 3 describe the epidemiology and present the clinical manifestations associated with the disease. Chapter 5 discusses the importance of data science as a tool for COVID-19 informatics. Chapter 7 presents an important aspect of the pandemic that has to do with the impact in populations that lack proper health services or present pre-existing health conditions. Chapter 8 is an overview of the statistical methods that can be used to understand COVID-19 morbidity and mortality. Chapter 9 discusses the impact mathematical modeling and statistics can have in the treatment of COVID-19 patients. Finally, chapter 10 is an overview of all the experimental vaccines available to combat the COVID-19 pandemic. I hope this book becomes a referent for current and future generations of investigators interested in mathematical modeling and infectious diseases, and provides additional tools to understand the current pandemic.

Alfredo G. Torres
University of Texas Medical Branch
Galveston, Texas
USA

FOREWORD III

The pandemic of COVID-19, caused by the SARS-CoV-2 virus (Severe Acute Respiratory Syndrome Coronavirus 2), has shaken up our societies, with an intensity and effects not suffered by humanity for a long time. To date, there have been registered millions of deaths associated to COVID-19, and hundreds of millions of confirmed cases all around the world. Moreover, this pandemic has triggered not only a deep and global health crisis, but also an economic and social (without mentioning psychological, educational, *etc.*) crisis like never seen before.

In order to endure and overcome this major tribulation, the different human communities, guided by their respective administrations and governments, have been put to the test in multiple and severe ways, under the direct effects of the disease, and the performance of several therapeutical and non-pharmaceutical interventions and mitigation measures. Among others, we could mention: the severity of symptoms and disease evolution in serious and critical cases (including assisted ventilation), and the long-term effects; the lack of effective treatments, specially in the first stages; unstoppable death tolls and incidence rates, with increasing numbers of hospitalizations that press and even saturate the health care national systems; hygiene or sanitary measures (frequent hand washing, not touching the face, the generalized use of disinfection products, the use of masks, gloves, and glasses, *etc.*); the use of detection tests (as PCR); quarantines, home isolation and confinements; the implementation of severe social distancing and isolation measures (indeed curfews in some cases); mobility, travel, circulation and gathering restrictions, and closure of borders; reduction or suspension of nonessential activities, with loss of millions of jobs and increasing unemployment rates; total or partial closure of colleges and universities and the unequal and frequently improvised performance of on-line education; campaigns for tracing possible cases; vaccination programs; the psychological effects on mental health in the community; *etc.*

Hence, this picture entailed the scientific community to face to an unprecedented challenge, in order to appropriately assess and advise health authorities and decision-makers. Such a kind of complex phenomena appeals to multidisciplinary and interdisciplinary groups of experts to take their part in order to reach a comprehensive approach, able to deal with the many relevant and multifactorial aspects of COVID-19, as illness and as pandemic. Of course, topics as the epidemiological and clinical aspects of the disease are central, but not the unique ones. Other matters require to be understood, as the SARS-CoV-2 virology, or the COVID-19 pathophysiology and immunology; the study of temporal evolution of

infected individuals and their contagiousness; the lack of preparedness of the health care systems and the rapid reaction in Medicine research, including the development and access to vaccines; the population heterogeneity and the effects of mobility and human behavior in the spread of the disease; the role of health and social inequities; *etc.*

In this context, the appearance of scientific works, which organize and summarize a great part of the scientific job carried out, is of great value. In particular, if the subject is approached from a comprehensive and multidisciplinary perspective, considering the individual and collective levels, and their temporal and spatial evolution, the biological, socioeconomic, technological aspects, *etc.*, and its consequences for the societies in which it occurs, as the current work does. In addition, the case of this scientific work is especially interesting, since it highlights the role that Mathematical and Computational Modeling can play together with other related areas such as Data Science and Statistics, when dealing with this type of multidisciplinary phenomenon, for which is an excellent reference for researchers and decision makers on how to deal with this type of problem.

Based on all that has been said above, I hope that this book will help researchers and decision makers to better understand and evaluate the situations that can arise in the context of a complex problem such as that caused by the COVID-19 pandemic and the way to face it.

Victoriano Gabriel Covarrubias Salvatori
Head of the Council of Science and Technology of the State of Puebla
Puebla, Mexico

PREFACE

This book is a multidisciplinary work, dedicated to the current problems around the COVID-19 pandemic and which has been carried out by a group of specialists from various scientific institutions in Mexico, United Kingdom, Spain, France, Russia, Cuba, Belgium and India.

Although the book does not exhaust the subject, it is however the result of the authors' effort to convey, to a certain extent, a comprehensive approach. Therefore, although not all possible points of view and relevant matters are addressed, which make up the multidisciplinary dimension of the research that has been carried out around the COVID-19 pandemic and its associated virus SARS-CoV-2 with its variants of concern, those that have proven to be essential and accessible to the authors' competence and resources have been included.

The first chapter aims to give a comprehensive view of results from different scientific perspectives that have been useful for building and studying epidemiological mathematical models for COVID-19. The conclusions and predictions provided by these results, have been the source of key recommendations to decision-making in several countries.

In later chapters, the problem is approached from the epidemiological and from the clinical point of view which together encompass its individual and societal dimensions. As in all health problems both points of view are essential although their methods and analytical tools are different. However, both approaches complement each other to provide the understanding of the measures that contribute to solving problems and their negative effects, which is indispensable for a global approach to the problem. Mathematical modeling, to different degrees and at different times, is present in both approaches.

The epidemiology of COVID-19 requires analyzing and dealing with large volumes of data, through mathematical and statistical models, which allow studying the problem of transmission as a complex problem, by means of theoretical and computational resources. All these conceptual and operational tools are present in the book under a general and global approach.

The exclusive epidemiological perspective, is however insufficient. Clinical aspects such as: pathophysiology, clinical manifestations, pharmacological

treatment of COVID-19, among others, are also essential for understanding and coping with this disease. Chapters 2 and 3 attempt to provide a panoramic view of the epidemiological and clinical components of this multifaceted problem.

Chapters 4 and 5 attempt to advance in the direction of the modeling of epidemics and pandemics, by presenting and discussing techniques and procedures for analyzing and modeling data analysis, thus providing the conceptual and practical bases to solve or minimize the undesirable effects of the pandemic.

Chapters 4 and 6 introduce the reader to the modeling of epidemics through the use of mathematical models. Different perspectives and uses of the models are presented. Chapter 6 in particular is devoted to the study of the effect of population heterogeneity in the process of spread of COVID-19, which is essential for the study of the pandemic, and surprisingly relegated in the available literature, as compared with other topics. “Data Science” is addressed in chapter 5, and shows the process of transforming data into information, using standard procedures with a rich recent development. Data Science is an indispensable tool for a full understanding of the ways in which COVID-19 manifests itself, and the different interpretations.

Population heterogeneity is revealed not only by territorial distribution and demographic factors associated with different social groups, but also by existing social inequalities and biological factors that characterize the response of different individuals to COVID-19 such as age, sex, pre-existing comorbidities, *etc.* Chapters 7 and 8 are devoted to the study of these two interesting topics.

The scientific and methodological approach associated with the study of the presence of “social inequalities” in the evolution of the pandemic, provides essential methods to assess the influence of context in morbidity and mortality associated with COVID-19. Chapter 7 addresses this problem from a conceptual, methodological and practical point of view, showing examples of specific cases.

Chapters 8 and 9 combine quantitative measurement and a qualitative approach to assess and understand the severity, fatality, and impact (both short and long term) of a pandemic with explicit application to COVID-19.

In particular, for a better understanding of the impact of immunotherapy protocols with their modeling aspects, the Cuban protocol, implemented during the pandemic, is shown and developed as an example, of the role and application of mathematical and statistical models.

Chapter 10 addresses a fundamental strategy for the control and elimination of the pandemic, namely the production and application of vaccines. Two key problems are included:

- The conception, production and laboratory evaluation, through clinical trials in its various phases, including the extent and duration of immunity and protection, all encompassed by the clinical aspects of the problem.
- The massive application of strategies to control the disease, to anticipate new mutations and variants, and to build risk perception among the general population. This chapter shows the progress attained on an essential issue with a prospective view to curb and ultimately eradicate the pandemic.

At the end of the book we have included an appendix with a series of graphs, duly selected, that show relevant data on how the COVID-19 pandemic has evolved in different regions and countries of the world. Concretely, this group of charts show the time series of the rolling 7-day average of number of daily new confirmed COVID-19 cases and deaths in the countries with the largest number of accumulated confirmed cases of COVID-19 in the world, and some specific regions (the whole World, the European Union, and the continents of Asia, Europe, North America, South America, and Africa). These plots constitute a simplified snapshot of the pandemic, that would be useful to quickly summarize the whole picture.

The topics covered in the book will undoubtedly be useful for specialists from different areas who have been involved, either in scientific research or daily work, with the COVID-19 pandemic. Doctors from different specialties, epidemiologists, chemists, biologists, pharmacologists, immunologists, microbiologists, mathematicians, computer scientists, sociologists and specialists in data analysis, among others will be clear beneficiaries of the messages conveyed by the book.

It will also be useful to any reader who, without being a specialist in any of these areas, wants to have an overview of the extensive work that has been carried out, during the little more than a year and a half that has elapsed since the beginning of the pandemic today. The book provides a very complete picture of the meaning scope of multidisciplinary scientific work aimed at a common goal.

I must express deserved recognition and gratitude to all who, in one way or another, have made possible the final result of this multidisciplinary work, on a subject that is of fundamental importance for all humanity.

In the first place, our gratitude to all the authors, many of whom were immersed in their professional daily work of caring for COVID-19 patients in intensive care rooms in hospitals or in laboratories dedicated to the creation of vaccines and immunotherapeutic treatments, while they wrote their chapters.

We also want to thank the Council of Science and Technology of the State of Puebla (CONCYTEP) in Mexico and, in particular, the Head of the Council, Dr. Victoriano Gabriel Covarrubias Salvatori, who, on behalf of the State Government, provided his support for the fulfillment of this work.

Our thanks to the Scientific Directorate of the HM Hospitales of Spain, Research Foundation who provided us with an extensive database of their COVID-19 patients, which has been of great help in obtaining some of the results presented in this book.

A special recognition to Dr. Moisés Soto Bajo, for the valuable work done in the revision and composition of the book.

Andrés Fraguela-Collar
Professor and Researcher in Applied Mathematics
Faculty of Physics and Mathematics,
Autonomous University of Puebla
Puebla, Mexico

Dedication:

*In memory of those who died as a result of the
COVID-19 pandemic,*

*To all people, especially children, who have lost
a loved one due to the pandemic,*

*To healthcare workers who have been on the front
lines caring for COVID-19 patients,*

*To the scientists around the world, whose work
has been the striking force that will ultimately
control this pandemic.*

List of contributors

Andrés Fraguela Collar, Ph.D., Dr.Sci.

Multidisciplinary Center for Mathematical and Computational Modeling

Faculty of Physical Mathematical Sciences

Autonomous University of Puebla

Puebla, Mexico

Raúl Felipe-Sosa, Ph.D.

Multidisciplinary Center for Mathematical and Computational Modeling

Faculty of Physical Mathematical Sciences

Autonomous University of Puebla

Puebla, Mexico

Moisés Soto-Bajo, Ph.D.

CONACYT Researcher Chairs Program

Multidisciplinary Center for Mathematical and Computational Modeling

Faculty of Physical Mathematical Sciences

Autonomous University of Puebla

Puebla, Mexico

María Eugenia Jiménez-Corona, M.D.,

Department of Epidemiology
National Institute of Cardiology
Mexico City, Mexico

Manlio F. Márquez-Murillo, M.D.

Deputy Director Clinical Investigation
National Institute of Cardiology
Mexico City, Mexico

Daniel Manzur Sandoval, M.D.

Cardiovascular Intensive Care Unit
National Institute of Cardiology
Mexico City, Mexico

Gustavo Rojas-Velasco, M.D.

Cardiovascular Intensive Care Unit
National Institute of Cardiology
Mexico City, Mexico

Efrén Melano Carranza, M.D.

Cardiovascular Intensive Care Unit
National Institute of Cardiology
Mexico City, Mexico

Camelia Cruz Rodríguez, M.D.

Cardiovascular Intensive Care Unit

National Institute of Cardiology

Mexico City, Mexico

Arturo Arzate Ramírez, M.D.

Cardiovascular Intensive Care Unit

National Institute of Cardiology

Mexico City, Mexico

Francisco Javier González Ruiz, M.D.

Cardiovascular Intensive Care Unit

National Institute of Cardiology

Mexico City, Mexico

Gerardo Arteaga Cárdenas, M.D.

Cardiovascular Intensive Care Unit

National Institute of Cardiology

Mexico City, Mexico

María Alexandra López Polanco, M.D.

Cardiovascular Intensive Care Unit

National Institute of Cardiology

Mexico City, Mexico

xxk

Eduardo Alberto González Escudero, M.D.

Cardiovascular Intensive Care Unit

National Institute of Cardiology

Mexico City, Mexico

Edgar García Cruz, M.D.

Cardiovascular Intensive Care Unit

National Institute of Cardiology

Mexico City, Mexico

Luis Augusto Baeza Herrera, M.D.

Cardiovascular Intensive Care Unit

National Institute of Cardiology

Mexico City, Mexico

Luis Efrén Santos Martínez, M.D.

Cardiovascular Intensive Care Unit

National Institute of Cardiology

Mexico City, Mexico

Jorge X. Velasco-Hernández, Ph.D.

Institute of Mathematics

National Autonomous University of Mexico

Juriquilla, Querétaro, Mexico

Nicandro Cruz-Ramírez, Ph.D.

Artificial Intelligence Research Institute

Universidad Veracruzana

Xalapa, Veracruz, Mexico

Guillermo-de-Jesús Hoyos-Rivera, Ph.D.

Artificial Intelligence Research Institute

Universidad Veracruzana

Xalapa, Veracruz, Mexico

Sonia-Lilia Mestizo-Gutiérrez, Ph.D.

Faculty of Chemical Sciences

Universidad Veracruzana

Xalapa, Veracruz, Mexico

Horacio Tapia-McClung, Ph.D.

Artificial Intelligence Research Institute

Universidad Veracruzana

Xalapa, Veracruz, Mexico

Malay Banerjee, Ph.D.

Indian Institute of Technology Kanpur

Kanpur, India

Samiran Ghosh, Ph.D.

Indian Institute of Technology Kanpur

Kanpur, India

Vitaly Volpert, Ph.D., Dr. Habil.

Institut Camille Jordan

University Lyon 1

Villeurbanne, France

xxiii

Jorge Bacallao Gallestey, Ph.D.

Atherosclerosis Research and Reference Center

University of Medical Sciences

Havana, Cuba

Alfonso Casado Collado, Ph.D.

Department of Preventive Medicine and Public Health

School of Medicine

Autonomous University of Madrid

Madrid, Spain

Armando Humberto Seuc-Jo, Ph.D.

National Institute of Hygiene, Epidemiology and Microbiology

Havana, Cuba

Elly Mertens, Ph.D. Institute

of Tropical Medicine

Antwerp, Belgium

José Luis Peñalvo, Ph.D.

Institute of Tropical Medicine

Antwerp, Belgium

Karina García-Martínez, Ph.D.

Center of Molecular Immunology

Havana, Cuba

Patricia Luaces-Álvarez, Ph.D.

Center of Molecular Immunology

Havana, Cuba

Lizet Sánchez-Valdés, Ph.D.

Center of Molecular Immunology

Havana, Cuba

Kalet León-Monzón, Ph.D.

Center of Molecular Immunology

Havana, Cuba

Tania Crombet-Ramos, Ph.D.

Center of Molecular Immunology

Havana, Cuba

Rolando Pérez-Rodríguez, Ph.D.

Center of Molecular Immunology

Havana, Cuba

Barbara Dema, Ph.D.

The Jenner Institute

University of Oxford

Old Road campus Research Building, Oxford, UK

Sthefany Pagliari, Ph.D.

The Jenner Institute

University of Oxford

Old Road campus Research Building, Oxford, UK

Arturo Reyes-Sandoval, Ph.D.

Instituto Politécnico Nacional, IPN

Mexico City, Mexico

An Approach to COVID-19: Current Results, Perspectives and its Study with Mathematical and Computational Modeling Tools

Andrés Fraguela-Collar^{*1}, Moisés Soto-Bajo¹², Raúl Felipe Sosa¹³

*** Corresponding author:** fraguela@fcfm.buap.mx, Phone: +52 (222) 2295500 ext. 2129

¹ Autonomous University of Puebla, Puebla, 72570, Mexico

² CONACYT Researcher Chairs Program, Mexico City, 03940, Mexico

³ CONACYT Postdoctoral Stays Program, Mexico City, 03940, Mexico

Abstract. This chapter presents the COVID-19 pandemic as a complex problem, which has resulted in multidisciplinary and interdisciplinary research of unprecedented magnitude at the international level. In particular, the important role that mathematical and computational modeling has played throughout the different phases of the evolution of the pandemic is analyzed. Some of the most notorious achievements and difficulties in obtaining results with the use of mathematical

Andrés Fraguela-Collar (Ed.)

All rights reserved-© 2022 Bentham Science Publishers

models and computational simulations are discussed, and some proposals are presented about relevant and still pending tasks.

Key words: COVID-19, epidemiological model, sensitivity analysis, bifurcations, parameter identification, controllability, stabilization.

1 INTRODUCTION

1.1 Importance

Today, mathematical and computational modeling is an indispensable tool for the study of complex systems and phenomena. Mathematical Epidemiology and its application to the study of the COVID-19 pandemic has been a relevant example of the usefulness of this tool.

In this chapter, we analyze and conceptualize some aspects of the pandemic from different perspectives, according to its relevance when studying and representing mathematically this phenomenon. We summarize relevant, and basically quantitative information about “model calibration and assessment”.

We also review the mathematical and computational models which have been used to describe the pandemic and the main results they have yielded. This text has been written in such a way that the congruence between the first analysis phase and the second conceptual synthesis phase of modeling could be easily perceived, that, although arising in a disordered way, underlie all modeling processes.

Finally, without any pretensions to being exhaustive, we show some fundamental results achieved with these models until now, and we identify some relevant problems and suggest possible strategies for their solution from the perspective of mathematical and computational modeling.

This summary, dedicated to such a wide and complex topic, necessarily has to be brief, schematic, and incomplete. Consequently, the matter is developed without the deep insight devoted to different topics in the remaining chapters of the book, to which readers are redirected to deepen

into each corresponding topic.

Therefore, the goal of this chapter is, on the one hand, to offer a review of the scientific work in relation to the COVID-19 pandemic, having as backbone the mathematical and computational modeling; and on the other hand, to show the close link between scientific results achieved along a widespread multidisciplinary research, the demands of the decision making in different stages of the pandemic, and the proposing and resolution of problems by using mathematical and computational models.

In this chapter, we will review from a methodological point of view, how mathematical models for the study of COVID-19 have evolved, based on basic principles. With the modeling of the phenomenon as a directing vector, relevant aspects will be discussed and how they have been taken into consideration. Among others, we can mention the inclusion of NPI (non-pharmaceutical interventions); population heterogeneity, including vulnerability and variability of human behavior; the effect of mobility; mitigation measures; the intra-domiciliary, extra-domiciliary and intra-hospital dynamics; limited immunity, after recovery from the disease, or as a result of the application of vaccines; vaccination strategies; the genetic variability of the virus and its characteristics regarding the transmission and severity of the disease, etc.

Despite the large number of important results that have been obtained so far, we will show that there are still many nonminor problems that require an answer. We will also discuss the need for new ideas to deal with them; on the one hand, to obtain models that better represent the dynamics of COVID-19, and on the other, a more in-depth qualitative analysis of the models is needed.

Frequently, using very particular models, general conclusions have been drawn only from numerical simulations, which reproduce certain incidence data in the study areas. In addition, on many occasions, to carry out numerical simulations, the information required by the models is used, which does not even correspond to the place where the results are applied. In this context, in addition to obtaining new results of a general nature, the qualitative study would allow to encompass and confirm a large number of results of this type.

With the support of more complete and reliable databases and numerical simulations of

Epidemiology of COVID-19

María Eugenia Jiménez-Corona^{*1}, Manlio F. Márquez-Murillo²

*** Corresponding author:** mejimenez777@gmail.com, Phone: +52 555573-2911 ext. 21013

¹ Department of Epidemiology, National Institute of Cardiology, Mexico City, Mexico

² Deputy Director Clinical Investigation, National Institute of Cardiology, Mexico City, Mexico

Abstract. In the last days of December 2019, in a seafood market in Wuhan, China, an outbreak of pneumonia of unknown origin was identified and later reported to the World Health Organization (WHO) regional office through the International Health Regulations for its dissemination to WHO member countries. The WHO declared the outbreak of a Public Health Emergency of International Concern (PHEIC) on January 30th, and on March 11th, 2020, the WHO Director-General declared it a pandemic. Today, it has been spread to more than 200 countries. The SARS-CoV-2 pandemic could be considered the health event with the greatest impact worldwide in the last 100 years. As of March 11th, 2021, one year later, more than 17 million cases and 2,615,018 deaths have been registered. The clinical picture caused by SARS-CoV-2 ranges from mild to severe forms. Some require hospitalization and, in some cases, even treatment in Intensive Care Units is needed

due to multiorgan disease. Medium and long-term sequelae are still under investigation. The pandemic has affected health services in Mexico and all over the world, not only due to the hospital reconversion for the care of patients with COVID-19 in the face of the emergency, but also because the care of patients with other conditions has been delayed with a negative impact on the physical and mental health of populations. Likewise, it has deranged several social activities such as travel, commerce, and education.

Key words: Severe acute respiratory syndrome, antigens, antibodies, COVID-19, coronavirus, epidemic, epidemiology, fatality, mortality, outbreak, pandemic, PHEIC, population, preventive measures, SARS-CoV-2, spike protein, vaccines, zoonosis.

1 INTRODUCTION

1.1 Importance

It is essential to establish the origin and to follow the evolution of a pandemic to identify the factors that could allow to define health public actions and interventions for the containment and mitigation of such events. This knowledge can also help to prevent or reduce the frequency of new pandemics.

1.2 Preliminaries

Epidemics and pandemics have accompanied man throughout the history of mankind. The Spanish influenza pandemic in 1918, known as “the mother of pandemics” claimed the lives of more than 50 million people. In 1957-1958 and 1968, there were two other major epidemics also due to influenza viruses, the A virus (H2N2) and the influenza A virus (H3N2), respectively. The 1918-1919 pandemic is the benchmark against which all other epidemics and pandemics are compared, due to the unprecedented number of victims [1].

Various factors favor the emergence and reemergence of pathogens, as well as their spread, including population growth, the increase in disorganized urbanization, international travel, human migratory movements, and climate change [2, 3].

In this century, various threats to global public health have occurred, of which 70-80% are related to emerging or reemerging diseases of zoonotic origin (transmitted from animals to humans): SARS-CoV in 2003, influenza A(H5N1) virus in 2004, influenza A(H1N1) virus in 2009, MERS-CoV from the Middle East in 2012, influenza A(H7N9) virus in 2013, Ebola virus and the Zika virus in 2014, among others [4]. In this 21st century, the first virus that triggered the alarm of the World Health Organization (WHO) was the Severe Acute Respiratory Syndrome (SARS) coronavirus in 2003 in China [5]. In 2009, a less deadly pandemic than the 1918 pandemic was the result of a combination of genetic changes in the virus, and was the first pandemic of this century, caused by the influenza A (H1N1) virus, with Mexico as its epicenter. Worldwide, an estimated 151,700 to 575,400 deaths were caused by infection with influenza A(H1N1)pdm09 (2009 H1N1 Pandemic) virus during the first year that the virus circulated [6]. Later, this virus became a seasonal virus and to date circulates globally and is currently part of the composition of seasonal influenza vaccines [7].

2 CORONAVIRUSES OF PUBLIC HEALTH IMPORTANCE

Coronaviruses are an extensive family of viruses, some of which can cause diseases in humans (zoonoses), ranging from the common cold to severe clinical pictures. such as those caused by the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) identified in 2003. In 2012, another coronavirus of importance to public health that causes the Middle East Respiratory Syndrome (MERS-CoV), was identified in Saudi Arabia. In 2019, the SARS-CoV-2 coronavirus that causes COVID-19 emerged [8–10]. Although the three coronaviruses identified in 2003, 2012, and 2019, have had an impact on public health, there are large differences in the number of cases, deaths, and fatality rates (Fig. 1).

COVID-19 Pathophysiology, Clinical Manifestations, and Drug Treatment

Daniel Manzur Sandoval*¹, Gustavo Rojas-Velasco¹, Efrén Melano Carranza¹,
Camelia Cruz Rodríguez¹, Arturo Arzate Ramírez¹, Francisco Javier González Ruiz¹,
Gerardo Arteaga Cárdenas¹, María Alexandra López Polanco¹,
Eduardo Alberto González Escudero¹, Edgar García Cruz¹, Luis Augusto Baeza Herrera¹,
Luis Efrén Santos Martínez¹

* **Corresponding author:** drdanielmanzur@gmail.com, Phone: +52 555573-2911 ext. 24506

¹ Cardiovascular Intensive Care Unit, National Institute of Cardiology, Mexico City, Mexico

Abstract. COVID-19 is caused by a single-stranded RNA encapsulated betacoronavirus, known as SARS-CoV-2, implicated in the pandemic that started in China in 2019. Viral replication consists of five stages that culminate in the release of the new virion. The exaggerated inflammatory response of COVID-19 is characterized by an elevation of acute phase reactants such as C-reactive protein and ferritin. It is associated with an unfavorable clinical course, intensified

by abnormal activation of the protein complex called the inflammasome. When the immune response does not control the virus, lung tissue damage occurs that leads to the massive release of proinflammatory cytokines, producing acute respiratory failure syndrome. Vascular permeability is increased; interaction with coagulation factors develops disseminated intravascular coagulation and multiorgan failure. Up to 33% of cases can be asymptomatic. Clinical manifestations can be mild or severe and involve various organs and systems. Among the most commonly affected are: respiratory, cardiovascular, renal, and hematological and coagulation systems. Among the most representative laboratory data are: elevation of inflammatory markers (CRP, inflammatory cytokines, tumor necrosis factor), high levels of D-Dimer, elevation of troponin I, lymphopenia, thrombocytopenia, alteration of liver enzymes and kidney function. There are risk factors and comorbidities that contribute to the severity of the clinical picture (mainly cardiovascular and metabolic diseases): diabetes mellitus, high blood pressure, obesity, chronic lung diseases, cancer, and chronic kidney failure. There are also other genetic factors associated with the host's immunopathogenesis and response to SARS COV-2 infection. There are various imaging methods that allow adequate identification and involvement of the pulmonary and cardiovascular systems with great sensitivity and specificity (computed tomography and echocardiography). The pandemic imposed decisions with very little information regarding what may be useful as a therapeutic strategy. This uncertainty applies to the treatment indicated in the prevention phase, as well as to the different stages of severity of the disease. In many cases, treatments were applied without having gone through a trial phase but only with the theoretical support of its probable benefit. However, over time, controlled studies showed that they did not provide any benefit and that they could even have a deleterious effect. Other therapies still in use have shown contradictory results in the different clinical trials where they were tested. Very few therapeutic options have shown undisputable benefit so far. The only ones that can modify the presentation or course of the disease are vaccines, which have also been developed in record time and in controlled trials, and all those that have been approved showed a decrease in the risk of infection and in the risk of presenting a severe manifestation of the disease.

Key words: Angiotensin-converting enzyme, acute respiratory distress syndrome, asymptomatic infection, Beta-coronavirus, cardiovascular system, clinical manifestations, Caspase 1, Coronavirus, COVID-19, cytokine storm, dyspnea, echocardiography, Ferritin, hemo-phagocytosis, hypoxia, inflammation immune system, inflammasome, inflammatory response, Interleukin 6, lympho-histiocytosis, micro-angiopathy, Procaspase, Protein C, RNA, SARS-CoV-2, thrombosis, T lymphocytes, viral replication, respiratory failure.

1 INTRODUCTION

1.1 Importance

This chapter provides a comprehensive overview of three crucial aspects related to COVID-19 and its causal agent SARS-CoV-2. In the first place, it exposes the mechanisms of viral damage of SARS-CoV-2, its biochemical components, the inflammatory response it triggers, as well as the thrombotic phenomena it causes, all of which are essential to understand the pathophysiology of COVID-19. It also reviews the clinical manifestations of COVID-19 across a wide spectrum of clinical conditions, including both asymptomatic and mild and severe symptomatic forms. This is of great importance to provide early and adequate medical care and to achieve the highest possible reduction in mortality. Finally, it summarizes the scientific evidence supporting the therapeutic options available so far, all of them aimed at mitigating the systemic inflammation produced by cytotoxic damage and preventing related complications.

1.2 Preliminaries

COVID-19 is caused by the SARS-CoV-2 virus and until July 2021 it has caused more than 3.8 million deaths worldwide. Although the majority of patients do not require hospitalization, a minority present with severe illness with acute respiratory distress syndrome. Currently, more information is known about the transmission and clinical presentation of patients with SARS-CoV2

Modelling Epidemics: a Perspective on Mathematical Models and Their Use

Jorge X. Velasco-Hernández^{*1}

* **Corresponding author:** jx.velasco@im.unam.mx, Phone: +52 562-34389 ext. 320

¹ Institute of Mathematics of National Autonomous University of Mexico,
Juriquilla, Querétaro-76230

Abstract. In this text, we look at several mathematical models that have been constructed during the present pandemic to address different issues of importance to public health policies about epidemic scenarios and their causes. We start by briefly reviewing the most basic properties of the classic Kermack-McKendrick model and then proceed to look at some generalizations and their applications to contact structures, co-circulation of viral infections, growth patterns of epidemic curves, characterization of probability distributions and passage times necessary to parametrize the compartments that are added to the basic Kermack-McKendrick model. All of these examples revolve around the idea that a system of differential equations is constructed from

a specific epidemiological problem, has as a central and main theoretical and conceptual support the epidemiological, medical, and biological context that motivates its construction and analysis.

Key words: Mathematical models, COVID-19, Mathematical epidemiology, COVID population dynamics

1 INTRODUCTION

1.1 Importance

Here, we argue on the importance of theoretical and conceptual perspectives in modelling the COVID-19 pandemic. Fitting equations to data without a sound perspective on the biological feasibility of the model will provide a statistically significant fit but will also fall short of providing useful information for the management, mitigation, and eventual control of the epidemic.

1.2 Preliminaries

The epidemic of SARS-CoV-2 that started in late December 2019 in Wuhan, China, and became a pandemic by late January 2020, is still with us. Mathematical models have been used since the very early days to forecast and inform public health strategies and decisions geared to control or, at least, mitigate the impact of the epidemic. Epidemic models became a notoriety both in the academic, public health and popular realms. The epidemics of infectious diseases are social phenomena whose dynamics are strongly influenced by the inherent heterogeneity of human populations regarding age, gender, genetic profiles, physiology, preferences, education, socioeconomic level, religion, customs, etc. All of these factors induce high variability and uncertainty on the disease transmission process. To confront the epidemic, a large number of modellers used variants of the family of so-called Kermack-McKendrick models. The Kermack-McKendrick models were first published in a series of papers in early decades of the XX century. These models are compartmental in nature and follow the fate of the individuals in the population where an infectious disease is

present. One of the equations follows the prevalence of the disease, which, in the most classical SIR model, describes a bell-shaped curve with a unique maximum and where both initial growth and final decline are exponential in nature. This model originally was used to describe the bubonic plague epidemic [1]. Anderson G. McKendrick was a Scottish medical practitioner born at the end of the XIX century. He worked in Sudan and India where he learned mathematics by himself [2]. As a result from this experience, he published a first version of his now famous model [3], which later in his life was further developed with the help of W.O. Kermack in a series of landmark papers. In 1927, William O. Kermack and McKendrick started a series of papers entitled Contributions to the Mathematical Theory of Epidemics that together constitute the fundamental background of mathematical epidemiology [1, 4–7]. Infectious diseases are transmitted through contacts between susceptible and infectious individuals. The models that we will comment on in the following sections assume that all individuals are exactly equal and can be unequivocally classified into distinct classes that correspond to their physiological disease status: susceptible, exposed, infectious, recovered, quarantined, etc. During this long pandemic of SARS-CoV-2, many papers have been published where many more compartments are added to the basic transmission model (hospitalized, asymptotically infected, presymptomatically infected, isolated individuals and so on). This increase in the number of compartments gives the illusion of realism but at the price of increasing the number of parameters -two per new compartment- thus requiring either estimating all parameters or assigning values to some of them for the purpose of inference, simulation, forecast and prediction. Modelling has to deal with two problems, one is lack of identifiability, the other, overfitting. Many of the parameter values are taken from the medical and epidemiological literature and assumed to be true. This form of “parameter reduction” does not necessarily diminish the sensitivity of the model solutions to variations in these parameter values. Mathematical models are tools to study natural phenomena. Models can certainly be used to predict, but they can also be used to explain and understand the mechanisms and causes of a given natural phenomenon. Kermack-McKendrick models are excellent strategical tools of this type. Their objective is then not so much to forecast incidence, or number of deaths and hospitalized individuals, for example,

Data Science: A Useful Tool for Understanding SARS-CoV-2 Information Facts

Nicandro Cruz-Ramírez¹, Guillermo-de-Jesús Hoyos-Rivera*¹
Sonia-Lilia Mestizo-Gutiérrez² and Horacio Tapia-McClung¹

* **Corresponding author:** ghoyos@uv.mx, Phone: +52 2288 421700 ext. 10211

¹ Artificial Intelligence Research Institute, Universidad Veracruzana, Xalapa, Veracruz, Mexico

² Faculty of Chemical Sciences, Universidad Veracruzana, Xalapa, Veracruz, Mexico

Abstract. By the end of 2019, a local pneumonia outbreak in Wuhan, China, was determined to be caused by a novel form of coronavirus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which, since then, has spread worldwide thus becoming the most important public health issue of the beginning of the 21st century. As a response, governments and health organizations started collecting data about this disease for analyzing it, trying to draw conclusions that could lead to a better understanding of it, and eventually to alleviate its effects. Through the analysis of the available data, our area of interest has to do with finding possible correlations

among the variables related to COVID-19 cases which could give some insights. For example, which factors make a given patient to present an aggravated form of this illness, or even a higher risk of dying? Does the level of poverty make some people prone to get ill? What about the place where people live in? These and other questions can be answered based on the analysis of the available data. In this chapter, we give a brief introduction to Data Science (DS), a field of Artificial Intelligence (AI), and present some data analysis using publicly available COVID-19 data sets provided by the Mexican government. This allows us to show how AI tools and techniques can help us to better understand some aspects of this kind of situation, and in this way, hopefully helping health officials and providers to create better health policies and services and succeeding in their goal: saving lives.

Key words: Artificial Intelligence, Bayesian Network, COVID-19, Database, Data Science, Decision Tree, Entropy, Epidemiology, Health, Information, Knowledge, Pandemic, SARS-CoV-2, Workflow

1 INTRODUCTION

1.1 Importance

This chapter highlights the potential impact of Data Science, as a branch of Artificial Intelligence, in unveiling relevant associations related to COVID-19. Data Science provides tools to find meaningful associations from large databases, which can later be tested with more specific analytical techniques. A better understanding of the causation web around this disease is a key factor to design and implement strategies to cope with the pandemic.

1.2 Preliminaries

Ipsa scientia potestas est. This phrase means “knowledge itself is power”. It appears in *Meditationes Sacrae*[1], which was written by Sir Francis Bacon (1561-1626), and is of an

astonishing relevance at the present time. In fact, this was not the first time humankind realized that knowledge is worth, frequently even more than wealth. Other ancient references exist in this same sense, which confer great importance to knowledge.

But, what is knowledge, and is it really as important as we think? How is knowledge related to information and data? There is not a unified consensus on how these concepts are related, since each source assumes slightly different points of view, and even their definitions are constructed cross-reference to the other ones. For example, as stated in the Merriam-Webster dictionary [2], knowledge, information, and data are defined as:

Knowledge:

1. The fact or condition of knowing something with familiarity gained through experience or association.
2. The range of one's information or understanding.
3. The fact or condition of having information or of being learned.

Information:

1. Knowledge obtained from investigation, study, or instruction.
2. A signal or character (as in a communication system or computer) representing data.
3. Something (such as a message, experimental data, or a picture) which justifies change in a construct (such as a plan or theory) that represents physical or mental experience or another construct.

Data

1. Factual information (such as measurements or statistics) used as a basis for reasoning, discussion, or calculation.
2. Information in digital form that can be transmitted or processed.

Epidemic Progression in a Heterogeneously Distributed Population

Malay Banerjee¹, Samiran Ghosh¹, Vitaly Volpert^{*234}

* **Corresponding author:** volpert@math.univ-lyon1.fr, Phone: +33 472432765

¹ Indian Institute of Technology Kanpur, Kanpur - 208016, India

² Institut Camille Jordan, UMR 5208 CNRS, University Lyon 1, 69622 Villeurbanne, France

³ INRIA Team Dracula, INRIA Lyon La Doua, 69603 Villeurbanne, France

⁴ Peoples Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya St,
Moscow, 117198, Russia

Abstract. The chapter is devoted to a compartmental epidemiological model of infection progression in a space-distributed multipatch population with communication between the patches due to the movement of individuals. The subpopulations inside the patches consist of different groups with respect to the intensity of disease transmission both within and between groups. The heterogeneity of the population and its transfer between the patches influence the rate of epidemic

Andrés Fraguera-Collar (Ed.)

All rights reserved-© 2022 Bentham Science Publishers

progression, the final size of the epidemic, and the number of infected individuals.

Key words: COVID-19 epidemiology, heterogeneous population, multipatch model

1 INTRODUCTION

1.1 Importance

Heterogeneous populations with subpopulations differing in the rate of disease transmission are described with compartmental epidemiological models. Basic reproduction number (BRN), the final size of epidemic, and the maximal current number of infected individuals are determined. It is shown that BRN is not sufficient to determine the epidemic progression in a heterogeneous population. Multipatch models for spatially distributed populations are considered.

1.2 Epidemiological Situation

In the beginning of the second year of the COVID-19 pandemic, we can identify several consecutive stages of its progression. The initial stage with the exponential growth of the number of infected individuals was followed by the next stage characterized by the alternation of more or less strict measures of social distancing and their relaxation, and by the quarantine of the infected individuals. In the absence of vaccines and efficient antiviral drugs against SARS-CoV-2 infection, these were the only available measures to restrain the epidemic progression together with basic sanitary measures such as masks and personal hygiene.

It became clear in early 2020 that a relatively high proportion of severe cases and mortality rates distinguish the coronavirus disease from the annual influenza epidemic for which collective immunity is reached after several weeks after the epidemic peak followed by the epidemic decay. This scenario is impossible for the COVID-19 pandemic because the public health system and, particularly, intensive care units become rapidly saturated and incapable of dealing with the flow

of COVID and other patients. Public authorities use measures of social distancing to balance between uncontrolled epidemic growth and economic losses due to reduced activity.

As a result of this strategy accepted throughout the world, according to the official statistics by March 2021, there were about 120 million of total cases of infection, and about 2.6 million of deaths, although these data can be strongly underestimated (at least for infected) due to the large number of asymptomatic and unregistered cases. The total number of cases largely varies between the countries: 5-10% in Europe and USA, and much less in China and some other Asian countries. According to recent estimates, the number of deaths in the USA is about 15% more in 2020 compared to the previous year, with this increase related to the COVID-19 pandemic. A similar death rate increase can be expected in a number of European countries, but, as for the number of infected individuals, it can be substantially less in some Asian countries. There can be many reasons for such large disparities, but it is unclear which of them are the most influential.

The third stage of the epidemic started in January 2021 with the beginning of the vaccination campaign. By the middle of March, the vaccination was barely beginning¹ and the essential decrease in the number of newly infected individuals can only be expected after several months. Since the number of vaccines remains insufficient, the vaccination strategy adopted in many countries consists in the priority vaccination of more vulnerable elderly people and more exposed groups of the population, such as medical workers.

One of the important questions which determines the further evolution of the epidemiological situation concerns the duration of the immunity of the recovered and vaccinated individuals. In the case of recovered individuals, the level of antibodies and their persistence strongly depend on the severity of the disease [1–3]. Secondary coronavirus infections can be related to weak immunity or virus mutations. Reliable statistics on the number of repeated infections is not available, but it remains probably quite limited. The duration of immunity after vaccination is now estimated by 6 months (validity of vaccination certificates), but it can be eventually longer with an inter-individual

¹<https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html>

Social Inequalities in COVID-19

Jorge Bacallao Gallestey¹, Alfonso Casado Collado*²

* **Corresponding author:** Alfonsojaime.casado@inv.uam.es, Phone: +34 914975486

¹ Atherosclerosis Research and Reference Center. University of Medical Sciences, Havana, Cuba.

² Department of Preventive Medicine and Public Health. School of Medicine.

Autonomous University of Madrid, Spain.

Abstract. Social inequalities have become an essential component of the health situation analysis. Health statistics are incomplete if its basic indicators are not linked to socioeconomic, sociodemographic, or sociocultural strata. The evaluation of health systems' performance must include global indicators along with their distribution in social strata.

The COVID-19 pandemic has not affected all countries to the same extent. Global statistics of both, confirmed cases and deaths portray wide differences among countries.

Recent reports show wide differences associated with stratification criteria such as skin color or ethnic groups, sex, age, education, socioeconomic condition, and geographic area. The web of interactions between individual and contextual factors also influences the development of the new

Andrés Fraguera-Collar (Ed.)

All rights reserved-© 2022 Bentham Science Publishers

pandemic.

This chapter lays the conceptual basis for measuring social inequalities in health and presents a basic set of the most common indices. It underscores the fact that a metric choice is not only technical, but to a great extent depends on ethical and political considerations. We document social inequalities in several health indicators associated with COVID-19 using public data or information retrieved from recently published papers.

The first section of this chapter lays the conceptual foundations for measuring health inequalities. The second one exposes selected results and findings in different settings, and a brief analysis of the application of the inequality indices.

Key words: Concentration, COVID-19, dispersion, entropy, health disparity, health indicators, indices, inequities, right to health, social inequality, stratifying variables.

1 INTRODUCTION

1.1 Importance

This chapter provides methodological guidelines to measure social inequalities in the expression of COVID-19 indicators, and general suggestions for the use and interpretation of indices. It also includes illustrative applications and discussion of recent relevant examples. This will encourage the routine inclusion of inequalities to describe and monitor the current pandemic.

1.2 Preamble

The COVID-19 pandemic, which at the time of writing this text - April 1, 2021 - has already claimed the lives of 2.82 million people out of a total of about 129 million cases worldwide, does not affect all countries to the same extent, nor is it homogeneously distributed within a country. This lack of homogeneity has many causes. Some are natural: mortality is much higher in people over 60 years of age, and in those with associated comorbidities, such as high blood pressure

and chronic obstructive respiratory disease, regardless of their age. Health personnel in direct contact with patients are at greater risk. There are also recent indications that a certain genetic predisposition could be involved in an increased risk of poor outcome [1]. It is not possible to eradicate these causes.

Other causes, however, are related to unjust orders that imply lack of access to quality health services, precarious living conditions, and low perception of risk. Several of these causes are passed down from one generation to another.

The differences between the two causes, the natural and unavoidable, and the contextual and avoidable, mark a distinction between inequalities (or simple differences) and inequities (or unjust inequalities). This distinction between just and unjust, between avoidable and inevitable, imposes a marked attribute of subjectivity on the study of inequalities, which is added to the intrinsic difficulties of description or analysis, when choosing a metric.

To evaluate the design and implementation of coping strategies, monitoring the classic health indicators of incidence, cumulative incidence, or mortality is not enough. It is necessary to study the distribution of these indicators according to relevant population groups. The performance evaluation of a health system, to put it in statistical language, does not reduce to measures of position, but must also include measures of dispersion. Nor is it possible to limit oneself to negative indicators. Positive indicators such as access to a reliable diagnosis, vaccination, and quality health services that guarantee a better prognosis and better evolution of the disease must be included.

Along with the pandemic, an infodemic has been unleashed in the world that, although it generates considerable benefits in the cognitive order, also carries with it high levels of disinformation and a great danger denounced by the World Health Organization (WHO) itself [2].

The vast theme evoked by the title of this chapter can be considered from three related, but essentially different, approaches. One of them is the impact of social inequality on the severity of the pandemic. This approach would explain at least part of the large gaps between countries and why some have performed better than others. A second focus is on the foreseeable consequences

Statistical Approaches to Understand COVID-19 Severity and Fatality

A.H. Seuc^{*1}, E. Mertens², J.L. Peñalvo²

*** Corresponding author:** ahseuc@gmail.com, Phone: +53 52595285

¹ National Institute of Hygiene, Epidemiology and Microbiology, Havana 10300, Cuba.

² Institute of Tropical Medicine, 2000-Antwerp, Belgium.

Abstract. Statistical methods are essential tools for confronting the current COVID-19 pandemic. These include approaches for quantifying the health impacts of the pandemic, methods for identification of patterns, or risk stratification, for estimating the risk of individuals to become infected, and of patients to die, and important clues on how to approach prediction models in a comprehensive way. The purpose of this chapter is to review basic statistical concepts related to characterization of COVID-19 severity and provide an application of a real scenario related to the identification of predictors of COVID-19 fatality in evolving databases. Some other statistical descriptions and comments are made of problems drawn from real situations.

Andrés Fraguera-Collar (Ed.)

All rights reserved-© 2022 Bentham Science Publishers

Key words: COVID-19, Statistics, Epidemiology, Prediction models, Health impact, Stratification, Severity, Fatality, Cuba

1 INTRODUCTION

1.1 Importance

Several approaches play an essential role in confronting the COVID-19 pandemic, among them are sociological and mathematical approaches. It is also important to emphasize the role of statistics in helping countries, societies, and the international community to understand and confront this pandemic in an efficient and sustainable manner.

1.2 Preliminaries

Statistics is a methodological discipline with roots in probability and mathematics. Statistics focuses on the variability of data, aiming to explaining it with statistical concepts and based on the knowledge of a particular context. The analysis of individual units (e.g. only one country) or situations (e.g. only developing countries) only offer a limited description of the issue. Statistics needs to use data from different units and from different situations so that inferences can be made from what has been observed, although with a certain level of uncertainty. Solutions to problems like the COVID-19 pandemic are in general based on comparisons.

Statisticians must understand well the context (e.g. biomedicine, sociology) on which statistical methods will be applied, as well as the complementary methodological disciplines that are available for a particular discipline. For example statistics often coincide with epidemiological methods to address medical research, such as the COVID-19 pandemic. Statistical thinking is key in facing the COVID-19 pandemic, and a correct calculation and interpretation of statistical and epidemiological indicators is necessary when characterizing the evolution of the outbreak, the prediction of future outcomes, and to inform the efficient allocation of healthcare resources to

mitigate current and future COVID-19 related burdens.

The purpose of this chapter is to review the basic statistical concepts related to the characterization of COVID-19 severity, and provide an application of a real scenario related to the identification of predictors of COVID-19 fatality in evolving databases.

2 BASIC STATISTICS APPLIED TO COVID-19 SEVERITY

2.1 Confirmed Cases, Severity, and Recovery or Death

When dealing with an outbreak of a new infectious agent it is priority to understand its severity as a main indicator of fatality. While at the individual level, severity is assessed by the gravity of signs and symptoms, at the population level, fatality ratios are calculated to assess the severity of disease and, when calculated for specific population subgroups, identify vulnerable groups and prioritize healthcare allocation of resources. Fatality rates can be calculated accounting for deaths among all infected individuals (infection fatality ratio, IFR) or deaths among confirmed cases (case fatality ratio, CFR). At the onset of the COVID-19 outbreak, only CFR could be calculated as only cases derived from surveillance systems and/or severe cases from reporting hospitals were available. Mild cases not seeking healthcare attention are common, and so is the proportion of asymptomatic individuals. These unaccounted cases introduce an important bias in CFR estimates stemming from the preferential ascertainment of severe cases, and delayed reporting, [1], and hinder the comparison of the infection severity across populations.

Underreporting is a particularly important issue in COVID-19 due to the magnitude of the crisis and the overloaded testing capacity of the health systems across the world [2]. As the pandemic evolves and testing becomes more available, CFR estimates will be more reliable but, especially when comparing populations, the limitations of the use of CFR should be acknowledged and methods to increase comparability should be applied, for example, by introducing time in the calculation by using a lag-time since first case reported in the country to avoid insufficient testing and delayed reporting [3]. Furthermore, it is advisable to report the period during which deaths

Understanding the Impact of Cuban Immunotherapy Protocols During COVID-19 Disease: Contributions from Mathematical Modeling and Statistical Approaches

**K. García-Martínez^{*1}, P. L. Luaces-Álvarez¹, L. Sánchez-Valdés¹
K. León-Monzón¹, T. Crombet-Ramos¹ and R. Pérez-Rodríguez¹**

*** Corresponding author:** karina@cim.sld.cu, Phone: +53 7 2717933

¹ Center of Molecular Immunology, Havana, Cuba

Abstract. Cuban protocols to treat patients with COVID-19 include interferon alpha 2B and anti-inflammatory therapy at different moments of the progression of the disease. Here, we present the results obtained using a mathematical model to study the immunopathology associated with COVID-19. Model simulations reproduce the clinical observations for the antiviral and

anti-inflammatory therapies and provide explanations for their efficacy from an immunological point of view. In addition, we present new data and statistical analysis of the clinical use of itolizumab, a humanized anti-CD6 antibody that reduces the secretion of multiple inflammatory cytokines. Authors concluded that the timely use of itolizumab can reduce the probability of death while its late prescription might not significantly reduce COVID-19 morbidity and mortality.

Key words: COVID-19, mathematical modeling, statistical analysis, itolizumab, interferon alpha 2B

1 INTRODUCTION

1.1 Importance

We develop a mathematical model for the dynamics of the immune response associated with COVID-19. Model results help to understand the effect of immunotherapies used in Cuban protocols on this infectious disease, and predict the best treatment strategies. We also present new clinical data for the use of itolizumab, a Cuban anti-inflammatory therapy. Statistical analysis of its efficacy in Cuban patients is in agreement with mathematical model predictions.

1.2 Preliminaries

COVID-19 is an acute respiratory disease caused by a highly pathogenic novel coronavirus SARS-CoV-2. The widely reported symptoms of COVID-19 are extremely variable, ranging from minimal symptoms to significant hypoxia with acute respiratory distress syndrome (ARDS) and multiorgan failure, which could be fatal [1].

COVID-19 is not a clear-cut disorder, but a gradually evolving pathology, characterized by a series of stages sustained by different molecular mechanisms. Earliest analyses of people with coronavirus in China suggested that it might not be the virus alone that damages the lungs and kills,

but an overactive immune response might also contribute [2]. The disease can hence be divided into different phases including a respiratory and a proinflammatory stage [3].

Type I Interferons (IFNs) play a primary role in the inhibition of viral replication through the coordination of antiviral immune responses and modulation of inflammatory responses. The type I IFN response in SARS patients was observed to be deregulated in patients that experienced adverse outcomes and severe disease [4]. In addition, the viral infection can lead to an excessive immune reaction in some patients, which is a hyperinflammatory state, known as cytokine release syndrome or cytokine storm [1].

Even though the exact immune mechanisms of COVID-19-mediated pathogenesis are still under investigation [5], we propose a mathematical model to explain the role of the innate and adaptive immune response in the outcome of the disease. We also present new data and statistical analyses of the clinical use of itolizumab, a humanized anti-CD6 antibody that reduces the secretion of multiple inflammatory cytokines.

2 MATHEMATICAL MODEL PRESENTATION

The immune response induced by COVID-19 involves several cells and molecules that play different roles depending on the stage of viral infection. The first response against the virus is mediated by components of the innate immune response, where the antigen presenting cells (APCs) have an important role in processing virus antigens and secreting Type I IFN that directly acts in inhibiting virus replication inside infected cells. This process helps to control virus expansion, but the total or partial elimination of the virus depends on the magnitude of this response. The second response is mediated by components of the adaptive immune response, where CD8+ T cells play a crucial role. These cells arrive to the site of infection with a time delay after virus entry to the system, differentiating into cytotoxic T cells after antigen recognition and interleukin-6 (IL-6) signaling. Cytotoxic T cells are able to kill infected cells and finally eliminate the virus from the system. In patients with deficiency in types of immune response, the presence of a higher virus load

Vaccines Against SARS-CoV-2. Eradicating COVID-19

Barbara Dema¹, Sthefany Pagliari¹, Arturo Reyes-Sandoval^{*12}

* **Corresponding author:** arturo.reyes@ndm.ox.ac.uk, Phone: +44 (0) 1865 287811

¹ The Jenner Institute, University of Oxford, Old Road campus Research Building,
Roosevelt Drive, Oxford, OX3 7DQ, UK

² Instituto Politécnico Nacional, IPN. Av. Luis Enrique Erro s/n.
Unidad Adolfo López Mateos, Mexico City, Mexico

Abstract. A year after the COVID-19 pandemic started, a global effort to develop vaccines and make them available to the public, has prompted a turning point in the history of vaccine development. The post-COVID era has accelerated the efforts to bring novel platform vaccine technologies such as nucleic acid or viral-vectored vaccines, which were proved to offer safety, efficacy, and speed in development and production, but have restricted records in the clinic. To date, five candidate vaccines have been approved for emergency use by different regulatory agencies

across the world, after demonstrating their robust immunogenicity response and efficacy against SARS-COV-2 infection. We summarize and analyse the progression of those vaccines with major research development and results in peer-reviewed journals.

Key words: COVID-19, SARS-CoV-2, vaccines, viral vectors, adenovirus, RNA vaccines, DNA vaccines, pandemic.

1 INTRODUCTION

1.1 Importance

Despite advances in many directions, from epidemiologic control to specific treatments, prevention based on immunization is the cornerstone of the strategy to cope with the pandemic. This chapter highlights its importance and exposes the uncertainties and challenges still remaining after more than one year of worldwide efforts towards safe and effective vaccines.

1.2 Preliminaries

Severe Acute Respiratory Syndrome coronavirus 2 (SARS-Cov2) is the newly discovered virus responsible for coronavirus disease 2019 (COVID-19). The COVID-19 outbreak reported in late 2019, emerged in the city of Wuhan (Hubei, China) and spread fast all over the world, making it a new public health concern [1, 2]. On 11 March 2020, the World Health Organization (WHO) officially had to consider the global COVID-19 outbreak as a pandemic due to the high number of cases continuing to disseminate at a remarkable pace in many worldwide territories.

Since the beginning of the COVID-19 pandemic, many effective measures have been taken in place to prevent the disease transmission, but most of these measures are not sustainable and have caused major disruptions to the economy as well as social and psychological issues. The ability of the virus to propagate in either symptomatic or asymptomatic patients made the control of the

disease is a real challenge for the authorities, and vaccination is the most important tool to protect against COVID-19 [3, 4].

The development of a new vaccine usually takes at least 10-15 years and needs to be evaluated for safety, immunogenicity, and efficacy in humans before it is licensed for use. An initial preclinical phase is conducted to identify a suitable target antigen. Both *in vitro* and *in vivo* evaluations will be performed to assess the ability of the new candidate to induce an effective immune response. The clinical phase intends to establish the safety and efficacy of a new vaccine in humans prior to its being licensed by regulatory agencies and getting into the clinic.

During a global health emergency, the development of a new vaccine must be accelerated to prevent and control the disease without compromising on safety. The COVID-19 vaccine has shown how fast a new candidate development can be achieved when sufficient resources are made available. With the recent COVID-19 pandemic, a new era in vaccinology using nucleic acid or viral vector technology has contributed to setting a fast-track development.

In this chapter, we highlight the different strategies that were introduced to develop a new COVID-19 vaccine since the start of the race for an effective and safe vaccine. We describe the current vaccines developed under different platforms and analyse the vaccines approved for emergency use based on results in peer-reviewed journals.

2 VACCINE DEVELOPMENT PROCESS

The development of a new vaccine is a result of a long process which involves several stages from laboratory research to regulatory submission for clinical trials. Regulatory agencies classify the process of the development of a new vaccine into preclinical (*in vitro* and *in vivo* animal tests) and clinical (clinical trials in humans) stages.

The preclinical phase is a requirement to take a new vaccine candidate from the laboratory to humans. The first step is exploratory and consists of the generation of the antigen that might induce an immune response and help to prevent the disease. A new antigen can be characterized

Appendix: COVID-19 in charts

In this appendix we present some charts which represent in some sense the evolution of the pandemic COVID-19. These graphics were retrieved on September 7, 2021 from the web page Our World in Data¹. The raw data on confirmed cases and deaths for all countries is sourced from the COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University².

The first and second group of figures show the time series of the number of daily new confirmed COVID-19 cases and deaths, respectively (their rolling 7-day average). Please note that the number of confirmed cases is lower than the number of actual cases, because of limited testing, and the number of confirmed deaths may not be an accurate count of the real number of actual deaths from COVID-19, due to limited testing and challenges in the attribution of the cause of death. Note also that these factors have been changing with time as new information about COVID-19 were available.

¹[Hannah Ritchie, Edouard Mathieu, Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino, Esteban Ortiz-Ospina, Joe Hasell, Bobbie Macdonald, Diana Beltekian and Max Roser (2020) - “Coronavirus Pandemic (COVID-19)”. Published online at OurWorldInData.org. Retrieved from: <https://ourworldindata.org/coronavirus> [Online Resource]].

²[Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Inf Dis.* 20(5):533–534. doi: 10.1016/S1473-3099(20)30120-1], <https://github.com/CSSEGISandData/COVID-19>.




Figure 1: Daily new confirmed COVID-19 cases for different regions. (a) World, (b) Asia, (c) Europe, (d) North America, (e) South America, (f) European Union, (g) Africa




Figure 2: Daily new confirmed COVID-19 cases for different countries. (a) United States, (b) India, (c) Brazil, (d) United Kingdom, (e) Russia, (f) France, (g) Turkey, (h) Argentina, (i) Iran




Figure 3: Daily new confirmed COVID-19 cases for different countries. (a) Colombia, (b) Spain, (c) Italy, (d) Indonesia, (e) Germany, (f) Mexico, (g) Poland, (h) South Africa, (i) Ukraine




Figure 4: Daily new confirmed COVID-19 cases for different countries. (a) Peru, (b) Philippines, (c) Netherlands, (d) Iraq, (e) Malaysia, (f) Czechia, (g) Chile, (h) Japan, (i) Canada




Figure 5: Daily new confirmed COVID-19 cases for different countries. (a) Bangladesh, (b) Thailand, (c) Belgium, (d) Pakistan, (e) Sweden, (f) Israel, (g) Romania, (h) Portugal, (i) Kazakhstan




Figure 6: Daily new confirmed COVID-19 cases for different countries. (a) Morocco, (b) Hungary, (c) Jordan, (d) Switzerland, (e) Serbia, (f) Nepal, (g) United Arab Emirates, (h) Austria, (i) Cuba




Figure 7: Daily new confirmed COVID-19 deaths for different regions. (a) World, (b) Asia, (c) Europe, (d) North America, (e) South America, (f) European Union, (g) Africa




Figure 8: Daily new confirmed COVID-19 deaths for different countries. (a) United States, (b) India, (c) Brazil, (d) United Kingdom, (e) Russia, (f) France, (g) Turkey, (h) Argentina, (i) Iran




Figure 9: Daily new confirmed COVID-19 deaths for different countries. (a) Colombia, (b) Spain, (c) Italy, (d) Indonesia, (e) Germany, (f) Mexico, (g) Poland, (h) South Africa, (i) Ukraine




Figure 10: Daily new confirmed COVID-19 deaths for different countries. (a) Peru, (b) Philippines, (c) Netherlands, (d) Iraq, (e) Malaysia, (f) Czechia, (g) Chile, (h) Japan, (i) Canada




Figure 11: Daily new confirmed COVID-19 deaths for different countries. (a) Bangladesh, (b) Thailand, (c) Belgium, (d) Pakistan, (e) Sweden, (f) Israel, (g) Romania, (h) Portugal, (i) Kazakhstan




Figure 12: Daily new confirmed COVID-19 deaths for different countries. (a) Morocco, (b) Hungary, (c) Jordan, (d) Switzerland, (e) Serbia, (f) Nepal, (g) United Arab Emirates, (h) Austria, (i) Cuba

SUBJECT INDEX

A

Abdominal pain 159
 Abnormalities 153, 155
 prothrombotic 153
 Accessibility, economic 326
 Acids, nucleic 468, 470, 475, 485
 Activation 150, 151, 152, 153, 154, 165, 172,
 177, 439, 449, 488, 494
 macrophage 165
 platelet 154, 172
 Activities 38, 153, 179, 492, 489
 fibrinolytic 153, 179
 neutralisation 492
 pseudovirus neutralising 489
 socio-economic 38
 Acute respiratory distress syndrome (ARDS)
 24, 25, 147, 152, 159, 161, 162, 175,
 393, 396, 436
 Adenosine nucleoside analog prodrug 168
 Adenovirus 469, 479, 495
 encoding 495
 Adhesion, platelet 154
 Adjuvancy, intrinsic 486
 Adverse 6, 148, 169, 171, 174, 175, 177, 178,
 480, 492
 effects 6, 175, 177, 178
 events 148, 169, 171, 174, 178, 480, 492
 Aerosols 17, 18, 19, 20, 128
 atmospheric 20
 Agents 17, 42, 59, 165
 infectious 150, 227, 389
 Air 71, 131, 166
 bronchograms 166
 conditioning systems 131
 traffic 71
 Akaike information criterion (AIC) 413
 Alveolar 161, 163
 damage 163
 inflammatory lesions 161
 Analysis 10, 56, 57
 demographic 56, 57

 theoretical 10
 Angiotensin 147, 150, 154, 161, 164, 489
 converting enzyme 147, 150, 161, 489
 Antibodies 28, 29, 31, 32, 166, 168, 452, 476,
 481, 482, 483, 492, 494, 495, 497
 inhibiting 495
 monoclonal 452
 Antibody 478, 483, 493
 dependent enhancement (ADE) 478
 responses 483, 493
 Anticoagulants 148, 153
 natural 153
 Antigenic targets 479
 Antigen(s) 110, 437, 438, 442, 445, 470, 474,
 475, 478, 479, 486, 487, 492, 493, 494
 presenting cells (APCs) 437, 438, 486
 surface 479
 target 470, 487, 492
 virus-related 445
 Antiinflammatory cytokines 152
 Arenaviruses 479
 Arrhythmias 159, 161, 164, 165
 lethal 165
 ventricular 165
 Artificial 120, 239, 244, 245
 intelligence 120, 239, 244
 neural networks (ANN) 245
 Aspergillosis 160
 Aspirations 321
 Asthma 402, 404, 406, 411, 412, 453, 454
 AstraZeneca 483
 COVID-19 vaccine 484
 Asymptomatic infections 29, 72, 147, 155
 Autoantibodies 159
 Autoimmunity 151
 Automatic theorem prover 244
 Autonomous vehicles 245

B

Bacteria 242, 475, 486
 Bacterial 475, 487

- contamination 487
- peptidoglycans 475
- Bayesian 49, 67, 68, 78, 239, 257, 258, 239, 257, 258, 260, 262, 263, 266, 267, 299
- estimation 67, 68
- networks (BN) 239, 257, 258, 260, 262, 263, 266, 267, 299
- statistics 49, 78
- Behavior 10, 42, 48
- dynamic 10
- reckless 48
- sigmoidal 42
- Bifurcation theory 81
- Binding antibodies 480, 489, 492
- anti-SARS-CoV-2 492
- Biological sense 10
- Biomedical sciences 324
- Blood flow, reduced 153
- Bootstrapping 397
- Bronchiectasis 166

- C**

- CanSinoBIO 480
- CanSino Biologics 480, 484
- Capacity 6, 44, 63, 321, 414, 440, 449, 479, 491
- boosting immunity 491
- prognostic 414
- Cardiomyopathy 159
- Cardiovascular 12, 146, 147, 159, 161, 163, 164, 454
- complications 161, 164
- disease 454
- system 12, 146, 147, 159, 163, 164
- Cases 4, 5, 20, 21, 23, 27, 32, 33, 34, 65, 77, 109, 113, 114, 115, 146, 173, 223, 228, 243, 250, 253, 356, 361, 388, 401, 420, 477
- asymptomatic 65, 77, 243
- atypical pneumonia 113
- mild symptomatic 20, 23
- primary coronavirus 228
- secondary coronavirus 228
- vaccinated 361
- Cells 440, 448, 483
- target 488
- virus-infected 440
- Cellular infiltrates 483
- Center 5, 471
- for biologics evaluation and research (CBER) 471
- for systems science and engineering (CSSE) 5
- Characteristics 20, 212, 369
- aerodynamic 20
- dynamics shares 212
- sociodemographic 369
- Chemokine concentrations 161
- Chemokines 151, 494
- Chess 166, 245
- world champions 245
- CT abnormalities 166
- Chikungunya 227
- Chimeric nature 479
- Chinese 4, 113, 480
- authorities 113
- company Cansino biologics 480
- ministry of health 4
- Chromosomal integration 487
- Chronic 156, 322, 401
- kidney disease 156, 401
- psychosocial stress 322
- Chronic malnutrition 329, 330, 332
- reducing 329
- Chronic obstructive 254, 256, 320, 402, 407, 411, 412, 415, 417, 453, 454
- pulmonary disease (COPD) 254, 256, 402, 407, 411, 412, 415, 417, 453, 454
- respiratory disease 320
- Coagulation 146, 150, 152, 153, 154, 177, 179
- cascade 153, 179
- disseminated intravascular 146, 152
- factors 146, 152, 154
- systems 146
- Coagulopathy 157, 162
- diffuse pulmonary intravascular 162
- Coefficient vector 395
- Cohort study 178

- Colds, common 39
- Collateral effects, supposed 243
- Combination 171
 - therapy 171
 - treatment 171
- Common abnormal radiographic findings 165
- Communication 229, 240
 - public 229
 - system 240
- Community 29, 34, 128
 - dispersion 34
 - outbreaks 34
 - transmission 29, 128
- Comorbidities 59, 60, 77, 155, 156, 246, 254, 256, 390, 392, 400, 401, 418, 419, 453, 454
 - medical 155
- Compartments 211, 475
 - infectious 211
 - innate immune 475
- Components 172, 221, 341
 - inflammatory 172
 - social 221
 - socioeconomic 341
- Computational 1, 2, 3, 8, 41, 76
 - machinery 76
 - modeling 1, 2, 3, 8, 41
- Computed tomography (CT) 146, 166
- Computer programs 245
 - implementing operational 245
- Conditions 24, 79, 81, 82, 110, 119, 125, 240, 326, 328, 329, 354, 357, 446, 447, 453, 456, 495
 - asymptomatic 446
 - critical 24, 447, 456
 - environmental stress 495
 - infectious 24, 66
 - prevalent concomitant 453
 - relative adverse economic 328
- Contagiers, silent 31
- Contagion 12, 17, 18, 19, 20, 22, 27, 28, 35, 48, 51, 61, 66, 71, 76, 82, 84, 243
 - capacity 19
 - chain 243
 - dynamics 82
 - long-range 20
 - process 12, 17
 - silent 27
- Containment 34, 110, 248
 - reinforced 34
- Contexts, socioeconomic 334
- Control 50, 53, 68, 118, 119, 208, 447, 448, 449, 453, 454, 455, 456, 469, 470
 - COVID-19 117
 - epidemiologic 469
 - threshold parameter 444
- Convalescent plasma (CP) 167, 168, 179, 482
 - therapy 168
- Coronavirus 4, 5, 110, 111, 113, 114, 147, 148, 226, 227, 228, 238, 309, 367
 - disease 4, 114, 277, 309, 367, 368, 469
 - epidemic 280
 - infection 226
- Corticosteroids 163, 176
- Coughing 17, 125, 128
- COVAX 114, 132
 - initiative 114
 - mechanism 132
- Covid-19 130, 163, 172, 320, 353, 392, 394, 395, 396, 459, 482
 - and chronic obstructive respiratory disease 320
 - contracting 130
 - death 459
 - diagnosis 392, 395
 - health contexts 353
 - severe 163, 172, 394, 396, 482
- COVID-19 disease 12, 16, 20, 24, 25, 83, 148, 311, 396, 438, 439, 440, 445
 - progression 311
 - severity 396
- COVID-19 13, 39, 44, 66, 75, 128, 130, 131, 160, 161, 162, 163, 164, 170, 175, 247, 265, 277, 387, 421, 437, 440, 447, 469, 470, 471, 473, 474, 476, 497
 - epidemiology 277
 - immunopathology 440
 - infection 13, 130, 131, 160, 161, 164, 175, 447
 - infectivity 66

- like disease 476
 - mediated pathogenesis 437
 - of infection 44
 - outbreak 247, 387, 469
 - pneumonia 162, 163, 170
 - symptoms 265
 - vaccines 39, 75, 470, 471, 473, 474, 497
 - virus 128, 421
 - COVID-19 illness 457, 489
 - preventing 489
 - Creatine kinase 172
 - Cumulative incidence of infections 367
 - Cytokines 153, 447, 448, 475
 - Cytokine storm 147, 151, 152, 161, 163, 165, 177, 437, 476
 - syndrome 165
 - Cytotoxic 147, 444, 449
 - cells 444, 449
 - damage 147
- D**
- Damage 17, 147, 148, 149, 151, 152, 154, 157, 161, 162, 163, 171, 179, 436, 447, 448, 449, 452
 - cellular 171
 - critical 448
 - diffuse 154
 - endothelial 154
 - host cell 452
 - lung 148
 - organ 149, 157, 161
 - organic 179
 - pulmonary 161
 - severe 17
 - skin 152
 - susceptible cell 448
 - tissue 154
 - viral 147
 - Damped oscillations 212
 - Data 250, 252, 265, 459, 270
 - collection process 270
 - sets 250, 265, 459
 - transformation 252
 - Deaths 50, 64, 67, 121, 122, 123, 125, 156, 220, 246, 349, 368, 387, 389, 390, 394, 396, 413, 414, 436, 440, 453, 456, 457, 459, 461
 - hospital 67
 - induce cell 440
 - natural 220
 - out-of-hospital 67
 - probability of 436, 453, 456, 459, 461
 - Degradation 486, 487
 - natural 487
 - Dementia 401, 405, 411, 412, 413, 414, 416, 417, 418, 419
 - Democratic relations 327
 - Dendritic cells 151, 438, 440, 441, 442, 444, 445, 447, 449, 486, 488, 494
 - promoters, activated 486
 - recruitment rate by Infected cells 442
 - Dengue 227
 - Dermal injections 492
 - Desirable 10, 79, 80, 331
 - attributes for health inequality indices 331
 - dynamics 10, 79, 80
 - Detection 24, 28, 29, 30, 34, 72, 157
 - of viral RNA 157
 - strategies focus 29
 - Development 120, 150, 229, 244, 245, 247, 325, 326, 327, 338, 449, 468, 470, 471, 473, 475, 488
 - clinical 488
 - critical 449
 - economic 327
 - fast-track 470
 - lowest socioeconomic 338
 - Deviation 80, 335, 361, 366
 - logarithmic 335, 361, 366
 - Devices 34, 241, 242, 244, 492
 - intelligent 244
 - protective 34
 - sensing 241
 - Diabetes 16, 146, 156, 127, 254, 256, 262, 265, 266, 267, 269, 402, 447, 453, 454
 - mellitus 146, 156, 402, 453, 454
 - Diagnosis 167, 168, 173, 179, 245, 320, 388, 390, 396, 400, 402, 413, 414, 418, 419

- early 179
 - medical 245
 - reliable 320
 - no symptoms at 402
 - Diagnostic tests 83, 119, 124, 126
 - performing 124
 - Diarrhea 158, 159
 - Dichotomy 354
 - Disability-adjusted life year (DALYs) 388, 389
 - Disease 6, 11, 13, 14, 16, 24, 25, 27, 31, 32, 38, 39, 53, 54, 58, 74, 81, 82, 110, 121, 127, 146, 148, 149, 156, 161, 163, 164, 166, 177, 210, 212, 214, 227, 254, 256, 276, 277, 279, 281, 282, 288, 289, 295, 298, 322, 323, 389, 393, 420, 436, 439, 447, 452, 453, 454, 456, 480, 469, 492
 - acute respiratory 436
 - asymptomatic 161
 - cardiometabolic 389
 - cardiovascular 16, 127, 156, 164, 254, 256, 447, 453
 - chronic lung 16, 146, 156
 - chronic non-communicable 322
 - chronic renal 254, 256, 453, 454
 - communicable 210, 322, 323
 - critical 177, 393, 452
 - emerging 121
 - free equilibrium (DFE) 212, 214, 282, 288, 289, 295, 298
 - immunosuppression 256
 - inflammatory 166
 - kidney 16
 - lower respiratory 492
 - metabolic 146
 - metastatic 156
 - multiorgan 110
 - neurological 148
 - onset 163
 - progression 269, 300, 311
 - propagation process 83
 - reemerging 111
 - respiratory 128
 - severity 172, 439, 453, 456
 - symptomatic COVID-19 480
 - transmission 276, 277, 279, 281, 469
 - transmitted 53
 - viral 31, 38
 - DNA 247, 474, 485, 486, 487, 488, 492
 - medicine 492
 - plasmid 486
 - transfected 487
 - DNases 486
 - DNA vaccines 469, 486, 487
 - and RNA vaccines 486
 - Drugs 120, 132, 148, 149, 169, 170, 177, 179, 277, 452, 456
 - anti-inflammatory 149
 - antiviral 456
 - efficient antiviral 277
 - immunomodulatory 454
 - Dynamics 9, 21, 22, 31, 41, 45, 46, 49, 61, 70, 71, 80, 81, 211, 212, 213, 248, 438, 444, 445, 446, 447, 448, 450, 451
 - cytokine 444, 448
 - epidemiological 9, 31, 45, 61, 80
 - of infectious diseases 41, 46, 248
 - propagation 41, 71
 - response kinetic 446
 - Dysfunction 24, 153, 155, 163, 165, 172, 322
 - acute organ 24
 - endothelial 153
 - endothelial cell 163
 - multiple organ 155
 - neuroendocrine 322
 - systolic 165
 - vascular 172
 - Dyspnea 147, 158, 159, 162
- E**
- Ebola virus 111, 479
 - Echocardiography 146, 147
 - Economic 36, 40, 63, 69
 - activities 63, 69
 - repercussions 36, 40
 - Economy 10, 11, 37, 69, 83, 118, 121, 218, 244, 469
 - globalized 118

- national 37
 - Edema 152, 162, 163
 - pulmonary 152
 - Effects 152, 438, 442, 444, 448
 - immunomodulatory 152
 - proinflammatory 438, 448
 - viral 442, 444
 - Electroporation 487, 492
 - Elevated transaminases 169
 - Elimination processes 439
 - Embolic complications 159
 - Emergency 36, 110, 114, 227, 229
 - post-coronavirus 227
 - Encephalopathy 159
 - Endocytosis 163
 - Endotheliopathy 153
 - Environment 34, 125, 128, 321, 324
 - ventilated indoor 125
 - Environmental 131, 323
 - measures 131
 - pollution 323
 - Epidemic 4, 7, 34, 49, 50, 64, 66, 68, 70, 72, 73, 74, 110, 118, 208, 210, 214, 223, 229, 279, 280
 - mitigated 64
 - smallpox 279
 - Epidemic 43, 71, 77, 80, 81, 207, 213, 300, 301, 310
 - dynamics 77
 - growth 300, 301, 310
 - indicators 310
 - outbreak 80, 81, 213
 - processes 43, 71
 - scenarios 207
 - Epidemiological 8, 69, 309
 - measures 69
 - processes 8
 - theory 309
 - Epidemiologists 228, 337
 - Epithelial cells 151, 152, 154, 161, 439
 - alveolar 154, 161
 - infected 439
 - Equations 45, 46, 54, 55, 65, 67, 209, 211, 282, 285, 286, 289, 290, 292, 293, 296, 440, 441, 444
 - dynamic 46
 - fitting 208
 - renewal 45, 46, 65, 67
 - Equilibrium 212, 214, 279, 288, 295, 298, 344
 - disease-free 212, 214, 288, 295, 298
 - point, stable endemic 212
 - thermal 344
 - Erratic oscillations 224
 - Escherichia coli* 493
 - European 471, 473, 482, 491
 - economic area (EEA) 471
 - medicines agency (EMA) 471, 473, 482, 491
 - Events 49, 153, 173, 323, 355
 - cerebral vascular 153
 - complementary 355
 - embolic 173
 - focal super-dispersion 49
 - traumatic 323
 - Exocytosis 150, 163
 - Expression 42, 44, 53, 58, 59, 151, 289, 290, 291, 327, 328, 337, 339, 341, 343, 486, 487
 - analytical 42, 53
 - long-lasting 487
- F**
- Facilities, computational 310
 - Factors 6, 7, 11, 12, 43, 46, 47, 59, 76, 79, 130, 146, 147, 153, 157, 221, 222, 265, 266, 267, 309, 310, 311, 322, 328, 331, 370, 414, 453
 - behavioural 310
 - biological 79
 - demographic 453
 - economic 328
 - environmental 130
 - genetic 146, 157, 322
 - mitigating 46
 - social 76, 322, 414
 - socioeconomic 331
 - stratification 331, 370
 - transcription 153

Failure 146, 152, 162, 324, 436
 chronic kidney 146
 multiorgan 146, 436
 multiple organ 152
 secondary right ventricular 162
 Fatal hypercytokinemia 152
 Ferritin 145, 147, 150, 152, 157, 172
 Fever 22, 128, 158
 Fibroblasts 154
 Fibronectin 154
 Finite-dimensional dynamical systems 81
 Fluid, bronchoalveolar 475
 Food and drug association (FDA) 168, 471, 489, 491
 Fraction 211, 494
 saponin 494
 susceptible 211
 Functions 46, 146, 150, 165, 169, 173, 227, 394
 cardiac 165
 cumulative incidence 394
 inhibitory 150
 kidney 146, 173
 liver 169
 periodic 227
 probability density 46

G

Gastrointestinal manifestations 161
 Genes 149, 324, 486, 487
 antibiotic resistance 486
 encoding, containing 487
 Gene expression 322, 487
 dysregulated 487
 Genetic stability 477
 Genome 12, 113, 115, 149, 150, 163, 487
 accumulation 163
 sequence 115
 sequence homology 113
 Global health emergency 470
 Glomerular filtration rate (GFR) 170, 173
 Glucocorticoids 172
 Glycoproteins 154, 493

 multiple platelet membrane 154
 Glycosylation 493, 494
 Good 471, 472, 488
 clinical practice (GCP) 472
 manufacturing practices (GMPs) 471, 488
 Growth 64, 209, 223, 301, 309, 311, 474
 initial 209, 223
 rapid 311
 rate of 301, 309, 311
 Guillain-Barré syndrome 159

H

Hazard function 395, 396
 cumulative baseline 396
 Hazard subdistribution 453
 Headache 128, 158
 Health 6, 16, 20, 38, 110, 118, 119, 121, 225, 269, 319, 321, 322, 323, 324, 325, 326, 327, 328, 332, 333, 338, 346, 349, 350, 390
 care systems 225, 390
 damage 20
 global 16, 118
 mental 6, 38, 110, 121
 plans 327
 policies 324, 325, 327
 problems 269, 322, 327
 programs 333, 350
 promotion 127, 325, 333
 resources 349
 Health risks 116, 117, 219, 321
 acute public 116
 severe 219
 Health systems 27, 49, 63, 64, 65, 77, 277, 320, 326, 331, 339, 387
 comprehensive 326
 public 277
 Heart failure 161, 164, 165
 Helical tachyarrhythmia 165
 Hematological 146, 172
 alterations 172
 Hematologic malignancies 156
 Hemophagocytosis 161

- Hemo-phagocytosis 147
Hemoptysis 158
Hemorrhage 162
 pulmonary 162
Hemostasis 173
Hemostatic disorders 153
Hepatitis 170, 176, 479
Herpesviruses 479
High 157
 creatine phosphokinase 157
 lactate dehydrogenase 157
 liver enzymes 157
Hill-climbing procedure 261
Home 34, 63, 64
 isolation 34, 64
 quarantine 63, 64
Hospital 27, 42, 124, 173, 394, 395, 459
 admission 42, 124, 173, 394, 395, 459
 infrastructure 27
Host's immunopathogenesis 146
Human 111, 256, 362, 364, 365, 372, 479, 480
 adenoviruse serotype 480
 development index (HDI) 256, 362, 364, 365, 372
 migratory movements 111
 vaccination 479
Hyaline membranes 162
Hydrocortisone 174, 176
Hygiene, epidemic-related 304
Hyperferritinemia 152, 153
Hyperglycemia 174
Hypertension 16, 127, 156, 162, 229, 262, 269, 401, 447, 453, 454
 pulmonary 162
Hypotension 165
- I**
- IFN 442, 450, 497
 inhibition of viral production 442
 injection treatment 450
 T-cell response 497
IFN production 445, 447
 by dendritic cells 445
- IFN response 437, 446
 in SARS patients 437
Illnesses 24, 120, 147, 155, 218, 239, 331, 337, 347, 453
 critical 24, 155
 moderate risk 120
 severe 147
Imaging 155
 ground-glass 155
Immune response 17, 18, 31, 32, 152, 163, 436, 437, 438, 440, 443, 444, 445, 447, 448, 449, 475, 479, 478, 480, 482, 486, 488, 494, 496, 497
 adaptive 31, 437, 440, 445, 479
 antiviral 437, 447
 cell-mediated 496, 497
 cellular 475, 482, 496
 humoral 486, 488, 496
 innate 437, 494
 memory 32
 robust adaptive 479
 robust humoral 478
Immune system 13, 31, 32, 82, 147, 150, 151, 152, 442, 445, 446, 449
 innate 151, 152
 response 445, 446
Immunity 14, 16, 31, 39, 42, 45, 47, 51, 52, 53, 60, 63, 65, 74, 75, 150, 154, 211, 212, 475, 479, 489, 496
 factor 47
 humoral 475
 innate 154, 479
 natural 14, 16, 31
 permanent 60
 protective 150, 489, 496
Immunizations 351, 469, 472, 484, 485, 496
 mucosal 484, 485
Immunochromatography 29
Immunogenicity 470, 471, 472, 475, 476, 478, 480, 481, 482, 483, 484, 485, 486, 490, 492
Immunological memory 32
Immunomodulatory 149, 456
Immunopathology 435, 438, 439
Immunostimulants 494

- Immunosuppression 16, 254
- Immunotherapies 436, 438, 459
- Inactivated vaccines 475
 - traditional 475
- Index 328, 331, 332, 333, 335, 337, 339, 340, 342, 358, 360, 361, 362, 363, 365
 - homonymous 337
- Indicators 332, 337, 341, 344, 345, 347, 366
 - morbidity 347
 - socioeconomic 332, 337, 341, 344, 345, 366
- Individuals 14, 19, 28, 44, 50, 53, 54, 56, 57, 65, 74, 75, 77, 155, 209, 210, 213, 218, 219, 220, 226, 279, 280, 311, 387, 491
 - asymptomatic 28, 65, 75, 155, 219, 220, 387
 - immune 226
 - immunized 279
 - infectious 209, 213, 218
 - symptomatic 28, 50, 220
 - transmitting 280
- Induce 17, 165, 440, 470, 475, 486, 489, 494, 496, 497
 - dysfunction 165
 - gene expression 486
 - proinflammatory cytokines 494
- Inequalities 59, 37, 324, 331, 333, 342
 - economic 37
 - global 342
 - index 331
 - residual 333
 - socio-cultural 59
 - socioeconomic 229, 322, 355
- Infected 58, 70, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448
 - cell number 448
 - cells 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447
 - population 58, 70
- Infection 21, 28, 29, 30, 31, 32, 34, 39, 43, 59, 67, 74, 76, 125, 127, 130, 148, 150, 151, 152, 155, 161, 164, 171, 207, 215, 276, 367, 387, 437, 446, 449, 450, 451, 495
 - bacterial 171
 - blood 29
 - lower respiratory tract 495
 - process 43
 - progression 276
 - pulmonary 161
 - severity 387
 - viral 148, 150, 151, 152, 164, 207, 437, 449, 450, 451
- Infection rates 40, 44, 48, 126, 175
 - asymptomatic 126
- Infection/vaccination 226
 - primary 226
 - secondary 226
- Infectious diseases 38, 41, 42, 43, 46, 50, 53, 58, 71, 168, 172, 174, 208, 209
 - society of America (IDSA) 168, 172, 174
- Infectivity 13, 14, 17, 20, 28, 65, 73, 82, 219
 - viral 477
- Infiltration, macrophage 162
- Inflammasome 146, 147, 151, 179
- Inflammation 147, 151, 152, 153, 154, 165, 173, 449, 456, 459, 461
 - alveolar 154
 - endothelial 154
 - systemic 147
 - thrombus 153
- Inflammatory 16, 146, 149, 151, 157, 163, 323, 451, 461, 439, 447, 448, 449, 450, 451
 - biomarkers 461
 - cytokines 146, 157, 163, 447
 - damage 439, 447
 - processes 16, 149, 151, 323
 - reaction 448, 449, 450, 451
- Inflammatory response 145, 147, 150, 165, 174, 177, 179, 437
 - severe 177
 - systemic 177
- Inflammatory syndrome 152, 160
- Influenza 14, 28, 39, 58, 63, 110, 111, 116, 225, 226, 227, 228
 - virus 28, 39, 225, 226
- Influenza cases 228
 - primary 228
 - secondary 228
- Influenza vaccination 225
- Influenza vaccines 111, 39, 226
 - seasonal 111

Integrating equations 285
 Intensive) 64, 67, 109, 124, 156, 159, 173,
 214, 246, 254, 368, 369
 care units (ICU) 67, 109, 124, 156, 159,
 173, 214, 246, 254, 368, 369
 healthcare systems 64
 Interferons 16, 151, 163, 169, 437, 456
 International monetary fund (IMF) 40
 Internet of things (IoT) 178, 242
 Intramuscular vaccine immunisations 484
 Ischemic heart 401
 Itolizumab therapies 461

L

Lactic dehydrogenase 172
 LASSO regression shrinks 393
 Least absolute shrinkage and selection
 operator (LASSO) 392, 393
 Leucine rich-repeat (LRR) 151
 Leukocytosis 172
 Lipid 149, 487, 488
 membrane 149
 nanoparticles 487, 488
 Lipopolysaccharides 475
 Liver enzymes 146
 Lockdown 69, 218, 220, 221, 225, 227, 280,
 302, 303, 304, 309, 310
 complete 303, 304
 measures 310
 partial 220
 restrictions 303
 strict 218
 Low molecular weight heparin (LMWH) 173
 Lung disease 497
 vaccine-related eosinophilic 494
 Lung fibrosis 246
 Lung tissue 146, 152, 446
 damage 146, 446
 Lymphadenopathy 166
 Lymphocytes 147, 151, 152, 153
 Lympho-histiocytosis 147
 Lymphopenia 146, 150, 157, 161, 172, 177

M

Machine learning approaches 391
 Mackenback relative inequality index 339
 Malnutrition 329, 330
 Mammalian expression systems 493
 Management 8, 32, 125, 208, 265
 efficient patient care 390
 Marginalized minorities 323
 Markers 146, 452, 457, 483
 inflammatory 146, 457
 Marketing authorisation 472, 474
 application 472
 Markov condition 258, 263
 Mass action law 218
 Mathematical 2, 8, 208, 209, 310, 339
 artifact 339
 calculations 310
 epidemiology 2, 8, 208, 209
 Measles 58, 74, 75, 227
 Measuring social inequalities in relation 350
 Mechanical ventilation 156, 159, 167, 169,
 174, 175, 176, 177, 178, 393, 396
 Mechanisms 6, 8, 9, 115, 117, 147, 170, 171,
 172, 209, 242, 322, 323, 333, 474, 476
 coordination 117
 endocytosis 170
 genetic 322
 immunological 172
 inactivation 474
 pathogenic 476
 Mediators, pro-inflammatory 486
 Medicines and healthcare products regulatory
 agency (MHRA) 484
 Megakaryocytes 154
 Methods 57, 146, 247, 386, 400, 477
 analytical 57
 epidemiological 386
 image classification 247
 imaging 146
 machine learning 400
 microtitration 477
 Methylprednisolone 174, 175, 176
 Mexican 253, 265

COVID-19 database 253
 health system 265
 Micro-hemorrhages, producing 243
 Middle East respiratory syndrome 111
 Mitigation 3, 35, 47, 48, 60, 64, 67, 215, 219,
 220, 225, 227
 factors 47
 measures 3, 35, 48, 60, 215, 219, 220, 225,
 227
 policies 64
 strategies 67
 Moderna's vaccine 491
 Monocytes 151, 154, 442
 Monocytopoiesis 152
 Monte Carlo Markov chains (MCMC) 67
 Mucosal vaccination 485
 Municipality's 256
 education index 256
 health index 256
 income index 256
 Mutagenesis 475
 Mutations 4, 13, 479, 481, 487, 488, 490, 491,
 495
 proline 488, 490
 proline-stabilizing 481
 Myocardial 153, 161, 164, 165
 infarction 153
 injury 161, 164, 165
 ischemia 165
 Myocarditis 165

N

National medical products administration
 (NMPA) 480
 Nausea 159, 169
 Nebulization 227
 Needle-free biolistic transfection 487
 Network 70, 71, 242, 322
 metapopulation 70, 71
 Neurological 158, 159, 161
 complications 159
 symptoms 158, 161
 Neutralisation 483, 497

 assays 483
 Neutralising 476, 478, 480, 482, 483, 489,
 494, 495, 496
 antibodies 476, 478, 480, 482, 483, 489,
 494, 495, 496
 Neutrophils 151, 154, 162, 456, 457
 release factors 154
 Non-communicable diseases (NCDs) 322, 323
 Nuclear 486,
 membranes 151, 486
 transcription factor NFkB 151
 translocation 486

O

Obesity, morbid 127, 156
 Observations, epidemiological 21
 Onset, symptom's 459
 Open reading frame (ORF) 487
 Organs, secondary lymphoid 486
 Outbreaks 228, 238
 local pneumonia 238
 of coronavirus and influenza 228
 Oxygenation 24, 393
 extracorporeal membrane 393

P

Pamuk relative inequality index 339
 Pan American health organization (PAHO) 37
 Pandemic management 119
 Paramyxoviruses 479
 Partial thromboplastine time (PTT) 173
 Pathogen-associated molecular patterns
 (PAMPs) 151, 152, 475, 479
 Pathways, intracellular processing 479
 Percy-Keppel index 335, 343, 344, 361, 366
 Personal protective equipment (PPE) 119, 130
 Persons 19, 31, 66
 presymptomatic 66
 to-person transmission 19
 vaccinated 31
 Perspectives 8, 49
 complementary 8

- decision-making 49
- Phagocytosis 152, 494
- Phenotype 153, 154, 163
 - profibrotic 154
 - proinflammatory 153
- Phospholipids 494
- Plasmacytoid 494
- Pneumologists 7
- Pneumonia 4, 24, 26, 109, 114, 155, 161, 166, 174, 254, 256, 262, 266, 481
 - acute interstitial 161
 - mild 24, 26, 155, 161
 - viral 166
- Policies 69, 72, 74, 124, 219, 325, 333, 350
 - designed stepwise release 69
 - staggered-release 219
- Polymerase chain reaction (PCR) 23, 29
- Population 6, 29, 38, 45, 46, 51, 69, 77, 120, 210, 220, 279, 283, 284, 302, 304, 310, 332, 345, 347, 348, 350, 351, 356, 363, 366, 369, 399, 420
 - dynamics 45
 - homogeneous 283, 284, 302, 304
 - recovered 310
 - target 399
 - vaccinated 350, 356
- Posing mathematical problems 78
- Poxviruses 479
- Predictors of COVID-19 fatality 59, 385, 387, 399
- Prime-boost immunization strategy 476
- Probability 20, 21, 63, 215, 216, 258, 262, 264, 266, 267, 394, 395, 396, 397, 398
 - joint 258
 - predicted 398
- Probability distributions 23, 43, 44, 207, 214, 215, 335, 344, 345, 361, 366
- Process 6, 20, 31, 41, 42, 45, 70, 179, 211, 248, 249, 390, 418, 419, 437, 438, 439, 440, 441, 442, 444, 471, 473, 488, 491
 - clustering 390, 419
 - demographic 211
 - diffusion 20
 - dynamic 70
 - fast-tracked 473
 - homeostatic 439
 - infectious 179, 438
 - inhibition 439
 - manufacturing 488, 491
 - regulatory 471
 - virus-mediated 444
- Production 442, 486
 - cytokine 442
 - process 486
- Prognosis 168, 172, 392, 453
- Prognostic factors 399
- Programming language 245
- Proinflammatory cytokines 146, 151, 152, 153, 161, 177, 438
- Proinflammatory NLRP3 pathway 494
- Proline substitutions 495
- Propagation 6, 19, 70, 71, 80, 81, 486
 - global 70
- Properties 17, 25, 47, 58, 213, 218, 252, 280, 321, 332, 339, 344
 - analytical 332
- Prophylaxis 148, 173
 - antithrombotic 173
 - thromboembolic 173
- PROSPERO database 418
- Protease 150, 151, 495
 - cysteine 151
 - transmembrane serine 150
- Protection 481, 497
 - immune mediated 481
 - immunity 497
- Protective 164, 476, 491
 - effect 164
 - efficacy 476, 491
- Protein(s) 146, 147, 150, 151, 152, 154, 170, 471, 474, 488, 493, 494, 496
 - associated kinase 170
 - endogenous anticoagulant 154
 - inflammatory 151
 - production system 493
 - sensing 151
 - sensor 151
- Proteolytic cleavage 150
- Prothrombin time (PT) 157, 169, 173
- Pseudovirus-neutralising activity 489

Public health 5, 57, 69, 109, 113, 117, 120, 473
 applications 57
 emergency 5, 109, 113, 117, 473
 protecting 69
 response 120
 Public policies 210, 325
 proactive 325
 Pulmonary 159, 166
 embolism 159
 ultrasonography 166
 Pulmonary disease 402, 453, 495
 chronic obstructive 402, 453
 Pyrocytosis 151

R

Ratios, lymphocyte 456, 457
 Reactions, hypersensitivity 169
 Reactogenicity, systemic 490
 Receiver operating characteristics (ROC) 397, 456, 457, 459
 Recombinant 480, 482, 485, 478, 493,
 adenoviruses 482
 proteins 493
 vectored vaccines 478
 Recovery 24, 25, 31, 32, 37, 53, 54, 77, 169, 170, 171, 210, 214, 226, 246, 389, 390, 393, 394, 395, 456, 459
 economic 37
 rate 210
 times 25, 77, 169, 170, 171, 214
 Regression coefficients 392, 393, 396, 398
 Regulations, dysfunctional 163
 Reinforcement measures 53, 58
 Relative inequality index (RIKM) 339, 360
 Release, cytokine 171
 Reliable CFR estimates 388
 Renal clearance 442, 444
 Resample method 259
 Resources, social 321
 Respiration 114, 152, 171, 254, 442, 443, 445, 488
 diseases facility 254

distress 25
 epithelial cells 443
 failure syndrome 152
 infections 171
 syncytial virus (RSV) 442, 445, 488
 Respiratory syndrome coronavirus 4, 148, 155, 238
 human severe acute 148
 severe acute 4, 155, 238
 Response 63, 151, 445, 447, 469, 475
 cell-mediated 475
 immunodeficient 445, 447
 innate 151
 robust immunogenicity 469
 system 63
 Restrictions 7, 24, 34, 35, 40, 63, 69, 219, 303, 304
 blocking 69
 Retroviruses 479
 Rheumatoid arthritis 170
 Risk 35, 59, 60, 64, 117, 128, 129, 130, 133, 167, 177, 210, 218, 320, 322, 323, 390, 399, 473
 financial 473
 of contagion 35, 128, 210, 218
 propensity analysis 177
 RNA 12, 23, 113, 145, 147, 148, 149, 150, 469, 474, 485, 486, 487, 488, 492
 based vaccines 488
 encapsulated 149
 lipid-enveloped 113
 modifying enzymes 150
 replication machinery 487
 sensors 488
 single-stranded 145, 148
 vaccines 469, 486, 487
 viruses 148
 RNA-dependent RNA polymerase 150
 of SARS-CoV-2 168
 ROC analyses 457, 459

S

SamIam software 262

- Sanitary measures 34, 309
- SAR-CoV-2 109, 111, 114, 132, 146, 161, 164, 474 485, 492
- antigens 485
 - binding 161, 164
 - coronavirus 111
 - infection 146
 - pandemic 109, 114, 132
 - spike glycoprotein 492
 - virus 474
- SARS-CoV-2 6, 11, 12, 17, 20, 28, 63, 73, 83, 112, 131, 436, 490, 491
- infectious 490
 - neutralised 491
 - novel coronavirus 436
 - virus 6, 11, 12, 17, 20, 28, 63, 73, 83, 112, 131
- Secondary coronavirus infections 278
- Secretion 17, 439, 488
- cytokine 488
 - processes 439
 - respiratory 17
- Sensitivity analysis 2
- Sensory deficits 159
- Serological tests 28, 50
- Severe 22, 29, 110, 111, 113, 116, 126, 149, 155, 157, 159, 161, 167, 170, 215, 216, 217, 469
- acute respiratory syndrome (SARS) 22, 110, 111, 113, 116, 126, 167, 469
 - disease 29, 149, 155, 157, 159, 161, 167, 170, 215, 216, 217
- Shock 24, 165
- cardiogenic 165
 - septic 24
- Signals 71, 240, 248, 444
- propagated 71
- Signal transduction 153
- Simulations 2, 45, 49, 53, 63, 306, 307, 308, 310, 440, 442, 443, 445
- computational 2
- Situation 5, 6, 53, 58, 60, 61, 62, 70, 124, 330, 336, 354, 386
- adverse 354
 - national 124
- Skin color 318, 335, 367
- Smoke, cigarette 20
- Sneezing 17, 125, 128, 158
- Social 120, 121, 242, 245, 322, 323, 355,
- exposure factors 322
 - loads 355
 - manipulation 245
 - mobilization 121
 - network 120, 242
 - stigmatization 323
- Social distancing 38, 57, 64, 63, 69, 72, 220, 277, 278, 279, 309
- interventions 63
 - restrictions 69
 - strict 63
- Societies 11, 37, 64, 323, 324, 327, 328, 348, 349, 351, 355
- contemporary 327
- Socioeconomic 208, 318, 347, 355
- conditions 318, 347
 - gaps 355
 - level 208
- Space-distributed multipatch population 276
- Spanish 110, 354
- influenza pandemic 110
 - speaking population 354
- Spike 110, 113, 149, 480, 482, 491, 492
- glycoprotein 482
 - protein 110, 113, 149, 480, 491, 492
- Strategies 146, 249, 487
- systematic problem solution 249
 - therapeutic 146
 - transfection 487
- Stressors 323
- environmental 323
 - multiple 323
- Strict isolation measure 67
- Strokes 159
- Subsidiary analyses 170
- Suffocation 243
- Supplies, myocardial oxygen 165
- Suppression, mediated 443
- Surveillance systems 387
- Susceptible 56, 73, 82, 283, 293, 443
- cells renovation 443

population 56, 73, 82, 283, 293
 Symptomatic infection 155
 Symptoms 18, 19, 21, 22, 23, 24, 25, 26, 27,
 28, 30, 63, 119, 159, 165, 167, 168, 169,
 215, 216, 246, 396, 410, 414, 415, 417,
 459
 gastrointestinal 159, 169
 onset of 19, 22, 25, 27, 28, 30, 63, 159, 165,
 167, 168, 459
 recurring 26
 severe 25, 30, 215, 216, 246, 396
 Syndrome 24, 25, 147, 152, 159, 161, 165,
 393, 396, 436, 437, 456
 acute respiratory distress 24, 25, 147, 152,
 159, 393, 396, 436
 cytokine release 437, 456
 developed acute respiratory distress 161
 macrophage activation 152, 161
 System 68, 153, 212, 243, 282, 283, 284, 286,
 344, 345, 348, 349, 350, 437, 447, 448,
 449, 493
 banking 68
 hemostatic 153
 mammalian 493
 respiratory 243
 Systemic cytokines 165

T

Techniques 59, 65, 239, 400, 488
 analytical 239
 artificial intelligence 59
 bioreactor culture 488
 machine learning 65
 survival analysis 400
 Technology 50, 478, 479, 493
 recombinant protein 493
 Temporal 20, 220
 evolution of COVID-19 disease 20
 immunity 220
 Therapies 24, 146, 149, 150, 167, 173, 435,
 436, 447, 448
 anti-inflammatory 150, 435, 436, 447
 anti-viral 448

 oxygen 24
 renal replacement 173
 Thermodynamics 344
 Throat 19, 128, 158, 477
 sore 128, 158
 swabs 477
 Thrombin 154
 inhibiting 154
 signaling 154
 Thrombocytopenia 146, 157, 172
 Thromboembolism 153, 172
 pulmonary 172
 Thromboinflammation 153, 179
 Thrombosis 147, 153, 154, 172, 173
 arterial 153, 172, 173
 Thrombotic 152, 153, 154
 disorders 154
 microangiopathy 152, 153
 Tissue(s) 12, 128, 154, 164, 481, 438, 492
 cardiac 164
 factor, glycoprotein 154
 pulmonary 483
 Toll-like receptors (TLRs) 151, 488
 Transcription 150, 153
 genomic 150
 viral replicase 150
 Transformations 250, 349
 Transgene 479
 Transition hazards 394
 Transmission 10, 12, 17, 18, 20, 21, 22, 31,
 49, 52, 62, 63, 64, 65, 66, 68, 71, 73,
 125, 130, 131, 133, 215, 229, 479
 asymptomatic 52, 65, 66
 functions 479
 mechanisms 17, 125
 of COVID-19 68, 73, 133
 process 215
 reducing 64
 symptomatic 65
 Treatment 5, 6, 7, 13, 16, 25, 120, 146, 169,
 170, 171, 174, 440, 447, 448, 449, 452,
 459, 461
 etioloical 174
 preventive vaccination 440
 strategies 171, 447

- therapeutic protocols 83
 - Tumor necrosis factor (TNF) 146, 157, 161, 163, 492
- U**
- Ultraviolet radiation 20
- V**
- Vacation seasons 48
 - Vaccination 7, 31, 36, 38, 39, 40, 76, 79, 82, 83, 227, 278, 279, 354, 355, 356, 358, 359, 360, 361, 474, 480, 483, 489
 - booster 489
 - campaigns 7, 31, 36, 79, 82, 83, 227, 278
 - policies 7, 76
 - process 40
 - Vaccine(s) 76, 227, 475, 481, 482, 484, 491
 - candidate 482, 491
 - efficacy 76, 227, 484
 - heterologous recombinant adenoviral 482
 - live-attenuated 475
 - oral poliovirus 475
 - protection 481
 - Vaccinology 470
 - Vascular injury 162
 - Vasoconstriction 153
 - Vectors 3, 479, 478, 482, 493, 479
 - baculovirus expression 493
 - genome 478
 - replicant-deficit vaccine 482
 - replication-deficient virus 479
 - reproduction 479
 - vaccinia virus 479
 - Ventilation 20, 24, 25, 129, 130, 131, 163
 - excessive stress 163
 - Ventricular 165
 - fibrillation 165
 - tachycardia, sustained 165
 - Violence 323
 - Viral 112, 150, 161, 442, 470, 479
 - amplification 479
 - fusion 150
 - production 442
 - reservoirs 112
 - tropism 161
 - vector technology 470
 - Viral genome 150, 163, 487, 488
 - engineered 487
 - Viral replication 12, 149
 - cycle 149
 - process 12
 - Virions 19, 149
 - Virus(s) 4, 5, 12, 13, 14, 17, 18, 19, 20, 21, 23, 25, 27, 29, 30, 31, 34, 39, 40, 111, 112, 113, 148, 151, 152, 242, 278, 437, 438, 442, 444, 445, 446, 447, 449, 452, 461, 475, 474, 478, 479, 485, 488, 486, 490
 - contagious respiratory 14
 - cytopathic 151
 - fuse 488
 - genome 19, 113
 - infection 152, 438, 442, 444, 445, 446, 447, 448, 449, 452, 461
 - intact 490
 - mutations 278
 - pathogenic 148
 - respiratory syncytial 488
 - seasonal 111
 - simian 486
 - transmission 23, 27
 - vaccine 475
 - vesicular stomatitis 485
 - Virus replication 446, 448, 481, 483
 - process 438
 - Vomiting 159, 169
- W**
- World 13, 34, 36, 37, 38, 40, 109, 111, 113, 115, 129, 320, 321, 469, 471
 - Health Organization (WHO) 13, 34, 36, 37, 38, 40, 109, 111, 113, 115, 129, 320, 321, 469, 471
 - Trade Organization (WTO) 40
 - Worldwide efforts 469

Z

Zika virus 111

Zoonoses 110, 111



Andrés Fraguela Collar

Andrés Fraguela Collar is a research professor of applied mathematics at the Autonomous University of Puebla (Mexico). He received his Ph.D. degree and the Habilitation of the Doctorate in Science from Lomonosov State University and the Institute of Mathematics V.A. Steklov of the Russian Academy of Sciences. He is the author of more than 140 original theoretical and applied research papers, including book chapters and books, on topics that involve Functional Analysis and Differential Equations and their applications in epidemiology, neuroscience, cardiology and some industry problems. Dr. Fraguela has participated in 48 multidisciplinary research projects, more than 200 presentations at international conferences and has been an editor and reviewer in several scientific journals. He has been a distinguished visitor of the Complutense University of Madrid, Associate Professor at the M.V. Lomosov State University, Senior Scientific Collaborator of the Institute of Mathematics V.A. Steklov and Chair of Excellence of the National Council of Science and Technology of Mexico.